

Supplementary Material

Two-dose SARS-CoV-2 vaccine effectiveness (VE) with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

Supplementary Table 1. Variant of concern detection overall and by epidemiological week.....	2
Supplementary Table 2. Profile of participants by vaccine type, British Columbia.....	3
Supplementary Table 3. Profile of participants by vaccine type, Quebec	5
Supplementary Table 4. VE by vaccine type	7
Supplementary Table 5. VE against infection, by age group and vaccine type.....	8
Supplementary Table 6. VE against hospitalization, by age group and vaccine type.....	9
Supplementary Table 7. VE by sex and vaccine type	10
Supplementary Table 8. VE against Alpha and Delta variants, by vaccine type.....	11
Supplementary Table 9. VE against Gamma variant, British Columbia, by vaccine type	12
Supplementary Table 10. VE by time since vaccination (mRNA and ChAdOx1).....	13
Supplementary Table 11. VE by time since vaccination (and mRNA vaccine type)	14
Supplementary Table 12. VE by time since vaccination (mixed mRNA and mRNA/ChAdOx1)	15
Supplementary Table 13. VE against Delta, by time since vaccination (mRNA and ChAdOx1)	16
Supplementary Table 14. VE against Delta, by time since vaccination (and mRNA vaccine type)	17
Supplementary Table 15. VE against Delta, by time since vaccination (mixed mRNA and mRNA/ChAdOx1)	18
Supplementary Table 16. VE by time since vaccination, (and mRNA vaccine type), ≥ 70 years	19
Supplementary Table 17. VE by interval between doses (mRNA and ChAdOx1).....	21
Supplementary Table 18. VE by interval between doses (and mRNA vaccine type).....	22
Supplementary Table 19. VE by interval between doses and time since second dose, by vaccine type.....	23

Supplementary Table 1. Variant of concern detection overall and by epidemiological week, ≥18-year-old study participants, British Columbia and Quebec, Canada

In variant-specific analyses, cases were categorized as Alpha, Gamma, or Delta variants of concern (VOC)^{1,2}. In both provinces, the methods and sampling frame for genetic characterization of viruses evolved in response to changing epidemic patterns, case load and laboratory capacity. In British Columbia (BC), genetic characterization of all case viruses was attempted by whole genome sequencing (WGS) between weeks 22 and 35 as previously described,^{3,4,5,6} but with WGS applied to a subset only (10% random sample in addition to all hospitalized, vaccinated or outbreak-associated cases) between weeks 36-39 when the Delta variant almost solely contributed. In Québec,⁷ between week 22 and week 35, diagnosis of Alpha was foremost by RT-PCR single-nucleotide polymorphism (SNP) screen for signature mutations, with a subset identified by WGS. After week 35, most Alpha diagnoses were by WGS. Detection of Delta by RT-PCR SNP screen was confirmed by WGS until week 24 and thereafter foremost by RT-PCR screen alone with a subset identified by WGS. The Gamma variant was detected in Quebec by WGS.

As shown in the table below, in each province about two-thirds of case viruses overall in the current study were genetically characterized. In BC, 91% of all participant case viruses were genetically characterized between weeks 22-35 with Alpha and Gamma variants comprising an approximately equal share (49% and 43%, respectively) between weeks 22-25, but <25% combined between weeks 26-30 and <1% between weeks 31-35 when Delta represented 77% and 99% of all characterized viruses, respectively. Although just 30% of participant case viruses were characterized in BC between weeks 36-39, Delta comprised virtually all of these. In Quebec, the Alpha variant predominated over Delta in weeks 22-25 (97%) and 26-30 (77%) but with Delta predominating over Alpha from August to October, including weeks 31-35 (89%) and 36-39 (99%). Quebec did not detect any Gamma or Beta variants and BC detected a single Beta variant [not displayed below] among participant cases during the analysis period.

	British Columbia (BC)						Quebec					
	Total case viruses (N, column %) ⁸	Genetically characterized case viruses (N, row %) ⁹	Among genetically characterized viruses				Total case viruses (N, column %) ⁸	Genetically characterized case viruses (N, row %) ⁹	Among genetically characterized viruses			
			Delta (n, row %) ¹⁰	Alpha (n, row %) ¹⁰	Gamma (n, row %) ¹⁰	Non-VOC (n, row %) ¹⁰			Delta (n, row %) ¹⁰	Alpha (n, row %) ¹⁰	Gamma (n, row %) ¹⁰	Non-VOC (n, row %) ¹⁰
Overall	27439	17690 (64%)	16089 (91%)	772 (4%)	787 (4%)	41 (<1%)	17234	11830 (67%)	10095 (85%)	1735 (15%)	Not available	Not available
By epidemiological week												
22-25 (May 30-June 26)	1493 (5)	1245 (83%)	88 (7)	609 (49)	532 (43)	15 (1)	1227 (7)	819 (67)	26 (3)	793 (97)	NA	NA
26-30 (June 27-July 31)	1611 (6)	1452 (90%)	1114 (77)	112 (8)	213 (15)	13 (1)	1118 (6)	589 (53)	137 (23)	452 (77)	NA	NA
31-35 (August 1-Sept 4)	12588 (46)	11381 (90%)	11278 (99)	50 (<1)	40 (<1)	13 (<1)	6551 (38)	4065 (62)	3609 (89)	456 (11)	NA	NA
36-39 (Sept 5-Oct 2)	11747 (43)	3612 (31%)	3609 (>99)	1 (<1)	2 (<1)	0	8338 (48)	6357 (76)	6323 (99)	34 (1)	NA	NA

NA=Not available

¹ World Health Organization. Tracking SARS-CoV-2 variants. [Accessed 16 October 2021]. Available: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>

² Government of Canada. SARS-CoV-2 variants: National definitions, classifications and public health actions. [Accessed 16 October 2021]. Available: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/testing-diagnosing-case-reporting/sars-cov-2-variants-national-definitions-classifications-public-health-actions.html>

³ Skowronski DM, Setayeshgar S, Zou M, et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada. Clin Infect Dis. 2021 Jul 9:ciab616. Doi: 10.1093/ciab616. Online ahead of print.

⁴ Skowronski DM, Setayeshgar S, Zou M, et al. Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada. [Accessed 16 October 2021]. Available: <https://www.medrxiv.org/content/10.1101/2021.09.20.21263875v1>

⁵ Hogan CA, Jassem AN, Sbihi H, et al. Rapid increase in SARS-CoV-2 P.1 lineage leading to codominance with B.1.1.7 lineage, British Columbia, Canada, January-April 2021. Emerging Infectious Diseases 2021;27: [early release]. Doi: 10.3201/eid2711.211190. Available: https://wwwnc.cdc.gov/eid/article/27/11/21-1190_article

⁶ British Columbia Centre for Disease Control (BCCDC). COVID-19 VoC report. [Accessed 16 October 2021]. Available from: <http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data#variants>

⁷ Données sur les variants du SRAS-CoV-2 au Québec. Quebec City: INSPQ. [Accessed 16 October 2021]. Available from: <https://www.inspq.qc.ca/covid-19/donnees/variants>

⁸ Percentage of cases viruses by epidemiological period (column %)

⁹ Percentage of total case viruses genetically characterized overall and each epidemiological period (row %).

¹⁰ Percentage of genetically characterized viruses that were the specified variant of concern (VOC) overall and by epidemiological period (row %).

Supplementary Table 2. Profile of participants ≥18-year-olds, by vaccine type (regardless of time since vaccination), British Columbia, Canada

	Any two mRNA			BNT162b2 (Pfizer-BioNTech, Comirnaty)			mRNA-1273 (Moderna, Spikevax)			ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)		
	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)
Total N	7535	198	252803	5593	136	184987	1408	44	46596	652	17	8635
Age group (years)												
18-49	4958 (66)	29 (15)	148071 (59)	3700 (66)	16 (12)	110302 (60)	967 (69)	10 (23)	28821 (62)	252 (39)	1 (6)	2794 (32)
50-69	1795 (24)	60 (30)	61685 (24)	1295 (23)	37 (27)	42794 (23)	328 (23)	17 (39)	11716 (25)	393 (60)	14 (82)	5704 (66)
70-79	543 (7)	44 (22)	26476 (10)	399 (7)	34 (25)	19451 (11)	89 (6)	5 (11)	3774 (8)	6 (1)	2 (12)	109 (1)
80+	239 (3)	65 (33)	16571 (7)	199 (4)	49 (36)	12440 (7)	24 (2)	12 (27)	2285 (5)	1 (0)	0 (0)	28 (0)
Median (Interquartile range)	41 (30-57)	72.5 (62-82)	43 (31-63)	40 (29-56)	74 (64-84)	43 (31-63)	40 (30-54)	65 (52-81)	42 (31-59)	54 (43-59)	60 (55-63)	57 (45-61)
Sex												
Female	4143 (55)	84 (42)	147458 (58)	3075 (55)	55 (40)	108987 (59)	772 (55)	23 (52)	26244 (56)	261 (40)	7 (41)	3974 (46)
Male	3392 (45)	114 (58)	105345 (42)	2518 (45)	81 (60)	76000 (41)	636 (45)	21 (48)	20352 (44)	391 (60)	10 (59)	4661 (54)
Epidemiological week												
22-25 (May 30-June 26)	75 (1)	5 (3)	10331 (4)	65 (1)	5 (4)	8465 (5)	9 (1)	0 (0)	1318 (3)	3 (0)	0 (0)	452 (5)
26-30 (June 27-July 31)	303 (4)	12 (6)	31733 (13)	256 (5)	12 (9)	23013 (12)	28 (2)	0 (0)	4969 (11)	28 (4)	1 (6)	1384 (16)
31-35 (August 1-Sept 4)	3064 (41)	64 (32)	97628 (39)	2322 (42)	39 (29)	71807 (39)	538 (38)	17 (39)	17827 (38)	292 (45)	9 (53)	3209 (37)
36-39 (Sept 5-Oct 2)	4093 (54)	117 (59)	113111 (45)	2950 (53)	80 (59)	81702 (44)	833 (59)	27 (61)	22482 (48)	329 (50)	7 (41)	3590 (42)
Interval between doses												
21-34 days (3-4 weeks)	269 (4)	12 (6)	5907 (2)	173 (3)	6 (4)	3642 (2)	82 (6)	5 (11)	2027 (4)	7 (1)	0	50 (<1)
35-48 days (5-6 weeks)	748 (10)	12 (6)	17316 (7)	494 (9)	4 (3)	11820 (6)	223 (16)	8 (18)	4606 (10)	25 (4)	0	303 (4)
49-62 days (7-8 weeks)	2858 (38)	29 (15)	94445 (37)	2184 (39)	21 (15)	68418 (37)	447 (32)	4 (9)	18111 (39)	309 (47)	10 (59)	4442 (51)
63-83 days (9-11 weeks)	2309 (31)	63 (32)	89169 (35)	1732 (31)	46 (34)	65402 (35)	391 (28)	10 (23)	15485 (33)	265 (41)	6 (35)	3372 (39)
84-111 days (12-15 weeks)	1166 (15)	68 (34)	40215 (16)	869(16)	49 (36)	31225 (17)	234 (17)	14 (32)	5505 (12)	45 (7)	1 (6)	444 (5)
112+ days (16+ weeks)	184 (2)	14 (7)	5739 (2)	141(3)	10 (7)	4480 (2)	31 (2)	3 (7)	862 (2)	1 (<1)	0	24 (<1)
Time since second dose												
0-13 d (0-1 w)	940 (12)	20 (10)	22615 (9)	717 (13)	14 (10)	16156 (9)	199 (14)	6 (14)	4707 (10)	7 (1)	0 (0)	558 (6)
14-27 d (2-3 w)	378 (5)	8 (4)	28148 (11)	302 (5)	6 (4)	20709 (11)	65 (5)	1 (2)	5512 (12)	8 (1)	0 (0)	548 (6)
28-55 d (4-7 w)	1614 (21)	26 (13)	70047 (28)	1268 (23)	18 (13)	51929 (28)	248 (18)	4 (9)	13052 (28)	77 (12)	3 (18)	1504 (17)
56-83 d (8-11 w)	2261 (30)	55 (28)	74147 (29)	1667 (30)	40 (29)	53607 (29)	356 (25)	9 (20)	12943 (28)	248 (38)	7 (41)	2826 (33)
84-111 d (12-15 w)	1428 (19)	67 (34)	38993 (15)	1009 (18)	47 (35)	27629 (15)	261 (19)	13 (30)	6685 (14)	272 (42)	7 (41)	2948 (34)
112-139 d (16-19 w)	350 (5)	14 (7)	8837 (4)	234 (4)	6 (4)	6906 (4)	112 (8)	8 (18)	1749 (4)	39 (6)	0 (0)	242 (3)
140-167 d (20-23 w)	88 (1)	3 (2)	2376 (1)	62 (1)	2 (1)	1811 (1)	25 (2)	1 (2)	558 (1)	1 (0)	0 (0)	9 (0)
168-195 d (24-27 w)	130 (2)	0 (0)	2618 (1)	104 (2)	0 (0)	2069 (1)	26 (2)	0 (0)	547 (1)	0 (0)	0 (0)	0 (0)
196+ d (28+ w)	346 (5)	5 (3)	5022 (2)	230 (4)	3 (2)	4171 (2)	116 (8)	2 (5)	843 (2)	0 (0)	0 (0)	0 (0)
Median	66	76	57	64	74	57	71	90	56	82	77	74
Range (days)	0-252	2-231	0-265	0-252	2-214	0-265	0-247	2-231	0-253	0-144	41-99	0-157
Interquartile range (days)	40-90	51-99	33-81	39-88	51-95	33-81	40-101	55.5-111	31-80	66-98	67-90	49-93

Hosp = Hospitalized cases

Supplementary Table 2 Cont'd. Profile of participants ≥18-year-olds, by vaccine type (regardless of time since vaccination), British Columbia, Canada

	Mixed mRNA			Mixed ChAdOX1 plus mRNA		
	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)
Total N	533	18	21208	443	2	15034
Age group (years)						
18-49	291 (55)	3 (17)	8941 (42)	299 (67)	0 (0)	8445 (56)
50-69	171 (32)	6 (33)	7173 (34)	141 (32)	1 (50)	6475 (43)
70-79	55 (10)	5 (28)	3248 (15)	2 (0)	1 (50)	95 (1)
80+	16 (3)	4 (22)	1846 (9)	1 (0)	0 (0)	19 (0)
Median (Interquartile range)	46 (33-62)	69.5 (64-75)	56 (37-69)	44 (37-52)	63 (53-73)	47 (41-57)
Sex						
Female	295 (55)	6 (33)	12221 (58)	191 (43)	1 (50)	7958 (53)
Male	238 (45)	12 (67)	8987 (42)	252 (57)	1 (50)	7076 (47)
Epidemiological week						
22-25 (May 30-June 26)	1 (<1)	0	548 (3)	19 (4)	0 (0)	285 (2)
26-30 (June 27-July 31)	19 (4)	0	3748 (18)	15 (3)	0 (0)	1909 (13)
31-35 (August 1-Sept 4)	204 (38)	8 (44)	7990 (38)	171 (39)	2 (100)	5810 (39)
36-39 (Sept 5-Oct 2)	309 (58)	10 (55)	8922 (42)	238 (54)	0 (0)	7030 (47)
Interval between doses						
21-34 days (3-4 weeks)	14 (3)	1 (6)	238 (1)	1 (<1)	0	25 (<1)
35-48 days (5-6 weeks)	31 (6)	0	890 (4)	9 (2)	0	120 (<1)
49-62 days (7-8 weeks)	227 (43)	4 (22)	7916 (37)	119 (27)	0	4107 (27)
63-83 days (9-11 weeks)	186 (35)	7 (39)	8282 (39)	227 (51)	2 (100)	8295 (55)
84-111 days (12-15 weeks)	63 (12)	5 (28)	3485 (16)	73 (16)	0	2285 (15)
112+ days (16+ weeks)	12 (2)	1 (6)	397 (2)	14 (3)	0	202 (1)
Time since second dose			16947 (80)			
0-13 d (0-1 w)	24 (5)	0	1750 (8)	39 (9)	0 (0)	950 (6)
14-27 d (2-3 w)	11 (2)	1	1925 (9)	11 (2)	1 (50)	1115 (7)
28-55 d (4-7 w)	98 (18)	4	5064 (24)	102 (23)	1 (50)	3756 (25)
56-83 d (8-11 w)	238 (45)	6	7594 (36)	176 (40)	0 (0)	5833 (39)
84-111 d (12-15 w)	157 (29)	7	4677 (22)	114 (26)	0 (0)	3335 (22)
112-139 d (16-19 w)	4 (1)	0	182 (1)	1 (0)	0 (0)	45 (0)
140-167 d (20-23 w)	1 (<1)	0	7 (<1)	0 (0)	0 (0)	0 (0)
168-195 d (24-27 w)	0	0	1 (<1)	0 (0)	0 (0)	0 (0)
196+ d (28+ w)	0	0	8 (<1)	0 (0)	0 (0)	0 (0)
Median	71	76	63	68	34.5	64
Range (days)	1-144	23-104	0-224	0-118	27-42	0-134
Interquartile range (days)	56-86	52-93	38-82	46-84	27-42	43-82

Hosp = Hospitalized cases

Supplementary Table 3. Profile of participants ≥18-year-olds, by vaccine type (regardless of time since vaccination), Quebec, Canada

	Any two mRNA			BNT162b2 (Pfizer-BioNTech, Comirnaty)			mRNA-1273 (Moderna, Spikevax)			ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)		
	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)
Total N	5379	155	576827	4323	123	436106	914	25	123986	236	14	18826
Age group (years)												
18-49	3516 (65)	31 (20)	312770 (54)	2782 (64)	22 (18)	231848 (53)	630 (69)	8 (32)	71115 (57)	28 (12)	0 (0)	930 (5)
50-69	1298 (24)	31 (20)	159863 (28)	1059 (24)	23 (19)	121129 (28)	213 (23)	6 (24)	34872 (28)	154 (65)	6 (43)	9905 (53)
70-79	363 (7)	40 (26)	65616 (11)	313 (7)	35 (28)	52470 (12)	44 (5)	4 (16)	11321 (9)	49 (21)	5 (36)	6053 (32)
80+	202 (4)	53 (34)	38578 (7)	169 (4)	43 (35)	30659 (7)	27 (3)	7 (28)	6678 (5)	5 (2)	3 (21)	1938 (10)
Median (Interquartile range)	42 (32-57)	73 (59-82)	47 (34-65)	43 (32-57)	75 (62-82)	47 (34-66)	39 (30-54)	61 (44-82)	45 (32-62)	58 (55-69)	71 (67-79)	67 (58-75)
Sex												
Female	2359 (44)	86 (55)	230659 (40)	1917 (44)	67 (54)	171074 (39)	371 (41)	13 (52)	52049 (42)	150 (64)	11 (79)	9578 (51)
Male	3020 (56)	69 (45)	346168 (60)	2406 (56)	56 (46)	265032 (61)	543 (59)	12 (48)	71937 (58)	86 (36)	3 (21)	9248 (49)
Epidemiological week												
22-25 (May 30-June 26)	69 (1)	5 (3)	43045 (8)	62 (1)	4 (4)	34685 (8)	6 (0)	1 (4)	7172 (5)	7 (3)	1 (7)	2734 (15)
26-30 (June 27-July 31)	220 (4)	6 (4)	102224 (18)	186 (5)	5 (5)	76716 (18)	30 (3)	1 (4)	22017 (18)	6 (2)	0 (0)	4492 (25)
31-35 (August 1-Sept 4)	1864 (35)	52 (33)	182100 (31)	1482 (34)	41 (34)	136391 (31)	326 (35)	6 (24)	40328 (32)	90 (38)	4 (28)	5461 (29)
36-39 (Sept 5-Oct 2)	3226 (60)	92 (59)	249458 (42)	2593 (60)	73 (59)	188314 (42)	552 (61)	17 (68)	54469 (45)	133 (57)	9 (63)	6139 (33)
Interval between doses												
21-34 days (3-4 weeks)	423 (8)	17 (11)	23062 (4)	313 (7)	8 (7)	13898 (3)	94 (10)	7 (28)	8213 (7)	6 (3)	1 (7)	180 (1)
35-48 days (5-6 weeks)	464 (9)	6 (4)	34960 (6)	293 (7)	5 (4)	20439 (5)	142 (16)	1 (4)	11924 (10)	19 (8)	0 (0)	794 (4)
49-62 days (7-8 weeks)	1490 (28)	13 (8)	139531 (24)	1193 (28)	9 (7)	101395 (23)	260 (28)	3 (12)	33452 (27)	84 (36)	2 (14)	4876 (26)
63-83 days (9-11 weeks)	1575 (29)	41 (26)	179057 (31)	1283 (30)	37 (30)	134852 (31)	262 (29)	4 (16)	39908 (32)	105 (44)	8 (57)	10180 (54)
84-111 days (12-15 weeks)	908 (17)	45 (29)	122361 (21)	766 (18)	38 (31)	97199 (22)	122 (13)	6 (24)	22360 (18)	21 (9)	3 (21)	2354 (13)
112+ days (16+ weeks)	519 (10)	33 (21)	77856 (13)	475 (11)	26 (21)	68323 (16)	34 (4)	4 (16)	8129 (7)	1 (0)	0 (0)	442 (2)
Time since second dose												
0-13 days (0-1 weeks)	745 (14)	12 (8)	64574 (11)	616 (15)	10 (8)	48138 (11)	118 (13)	1 (4)	14125 (12)	6 (2)	1 (7)	1924 (11)
14-27 days (2-3 weeks)	324 (6)	16 (11)	72539 (12)	256 (6)	11 (9)	55110 (12)	63 (7)	3 (12)	15315 (12)	4 (1)	0 (0)	2185 (12)
28-55 days (4-7 weeks)	1234 (24)	26 (18)	162071 (28)	989 (23)	20 (16)	124151 (28)	212 (23)	5 (20)	33187 (27)	17 (8)	0 (0)	3970 (20)
56-83 days (8-11 weeks)	1743 (31)	41 (26)	156632 (27)	1358 (32)	29 (24)	116747 (27)	312 (34)	9 (36)	34862 (28)	62 (26)	3 (21)	4313 (23)
84-111 days (12-15 weeks)	941 (17)	48 (31)	80130 (14)	767 (18)	45 (37)	60368 (14)	160 (17)	3 (12)	17915 (15)	112 (47)	5 (35)	4872 (26)
112-139 days (16-19 weeks)	277 (5)	9 (6)	26489 (4)	238 (5)	7 (5)	20682 (4)	35 (5)	2 (8)	5286 (4)	34 (14)	4 (28)	1540 (8)
140-167 days (20-23 weeks)	87 (1)	2 (1)	12433 (2)	76 (1)	1 (1)	9721 (2)	9 (1)	1 (4)	2537 (2)	1 (0)	1 (7)	16 (0)
168-195 days (24-27 weeks)	19 (0)	0 (0)	1394 (0)	16 (0)	0 (0)	782 (0)	3 (0)	0 (0)	604 (0)	0 (0)	0 (0)	2 (0)
196+ days (28+ weeks)	9 (0)	1 (1)	565 (0)	7 (0)	0 (0)	407 (0)	2 (0)	1 (4)	155 (0)	0 (0)	0 (0)	4 (0)
Median	62	74	54	62	78	54	61	70	55	91	105	65
Range (days)	0-240	1-210	0-256	0-240	3-143	0-256	0-219	1-210	0-238	2-154	6-154	0-216
Interquartile range (days)	36-83	40-95	29-79	36-84	46-96	29-79	36-81	46-84	29-80	76-104	82-116	32-93

Hosp = Hospitalized cases

Supplementary Table 3 Cont'd. Profile of participants ≥ 18 -year-olds, by vaccine type (regardless of time since vaccination), Quebec, Canada

	Mixed mRNA			Mixed ChAdOX1 plus mRNA		
	Cases (n, %)	Hosp (n, %)	Controls (n, %)	Cases (n, %)	Hosp (n, %)	Controls (n, %)
Total N	142	7	16735	253	7	29110
Age group (years)						
18-49	104 (73)	1 (14)	9807 (59)	62 (25)	0 (0)	5974 (21)
50-69	26 (18)	2 (29)	3862 (23)	170 (67)	3 (43)	19143 (66)
70-79	6 (4)	1 (14)	1825 (11)	17 (7)	2 (29)	3287 (11)
80+	6 (4)	3 (43)	1241 (7)	4 (2)	2 (29)	706 (2)
Median (Interquartile range)	39 (32-51)	70 (61-92)	44 (31-65)	55 (50-59)	79 (61-87)	57 (51-62)
Sex						
Female	71 (50)	1 (14)	9199 (55)	164 (65)	2 (29)	15188 (52)
Male	71 (50)	6 (86)	7536 (45)	89 (35)	5 (71)	13922 (48)
Epidemiological week						
22-25 (May 30-June 26)	1 (1)	0 (0)	1188 (7)	0 (0)	0 (0)	762 (3)
26-30 (June 27-July 31)	4 (3)	0 (0)	3491 (21)	8 (2)	0 (0)	6282 (22)
31-35 (August 1-Sept 4)	56 (39)	5 (71)	5381 (32)	83 (33)	2 (28)	9599 (33)
36-39 (Sept 5-Oct 2)	81 (57)	2 (29)	6675 (40)	162 (64)	5 (72)	12467 (42)
Interval between doses						
21-34 days (3-4 weeks)	16 (11)	2 (29)	951 (6)	1 (0)	1 (14)	58 (0)
35-48 days (5-6 weeks)	29 (20)	0 (0)	2597 (16)	1 (0)	0 (0)	126 (0)
49-62 days (7-8 weeks)	37 (26)	1 (14)	4684 (28)	62 (25)	0 (0)	5289 (18)
63-83 days (9-11 weeks)	30 (21)	0 (0)	4297 (26)	128 (51)	1 (14)	15115 (52)
84-111 days (12-15 weeks)	20 (14)	1 (14)	2802 (17)	44 (17)	4 (57)	6159 (21)
112+ days (16+ weeks)	10 (7)	3 (43)	1404 (8)	17 (7)	1 (14)	2363 (8)
Time since second dose						
0-13 d (0-1 w)	11 (8)	1 (14)	2311 (14)	11 (4)	0 (0)	3382 (11)
14-27 d (2-3 w)	5 (4)	2 (29)	2114 (13)	7 (3)	0 (0)	3363 (12)
28-55 d (4-7 w)	33 (23)	1 (14)	4733 (28)	48 (19)	1 (14)	7334 (26)
56-83 d (8-11 w)	73 (51)	3 (43)	5023 (30)	118 (46)	2 (28)	9694 (33)
84-111 d (12-15 w)	14 (10)	0 (0)	1847 (11)	68 (27)	4 (57)	5230 (18)
112-139 d (16-19 w)	4 (3)	0 (0)	521 (3)	0 (0)	0 (0)	101 (0)
140-167 d (20-23 w)	2 (1)	0 (0)	175 (1)	1 (0)	0 (0)	5 (0)
168-195 d (24-27 w)	0 (0)	0 (0)	8 (0)	0 (0)	0 (0)	1 (0)
196+ d (28+ w)	0 (0)	0 (0)	3 (0)	0 (0)	0 (0)	0 (0)
Median	64	48	51	71	84	57
Range (days)	0-148	2-73	0-236	2-143	52-107	0-188
Interquartile range (days)	48-77	15-69	26-74	55-84	76-104	30-78

Hosp = Hospitalized cases

Supplementary Table 4. Two-dose vaccine effectiveness against infection and hospitalization (≥ 14 days post-vaccination), by vaccine type, ≥ 18 -year-olds, British Columbia and Quebec, Canada

	British Columbia				Quebec			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Infection								
Two any vaccines	7644	252349	88 (87, 88)	90 (89, 90)	5106	554883	83 (82, 83)	88 (88, 89)
Two any mRNA vaccines	6595	230188	88 (88, 89)	90 (90, 91)	4634	512253	83 (82, 84)	89 (88, 89)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comiraty)	4876	168831	88 (88, 89)	90 (90, 90)	3707	387968	82 (81, 83)	88 (88, 89)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	1209	41889	88 (88, 89)	91 (90, 91)	796	109861	86 (85, 87)	90 (90, 91)
Two mixed mRNA doses	509	19458	89 (88, 90)	91 (90, 92)	131	14424	83 (80, 86)	89 (87, 91)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	645	8077	67 (65, 70)	71 (69, 74)	230	16902	75 (71, 78)	73 (69, 77)
Two mixed ChAdOx1 + mRNA	404	14084	88 (87, 89)	90 (89, 91)	242	25728	82 (80, 84)	87 (85, 89)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Hospitalization								
Two any vaccines	197	252349	96 (95, 96)	98 (97, 98)	163	554883	91 (89, 92)	97 (96, 97)
Two any mRNA vaccines	178	230188	96 (95, 96)	98 (97, 98)	143	512253	92 (90, 93)	97 (96, 97)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comiraty)	122	168831	96 (95, 97)	98 (97, 98)	113	387968	91 (89, 93)	97 (96, 97)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	38	41889	95 (93, 96)	97 (96, 98)	24	109861	93 (90, 96)	97 (95, 98)
Two mixed mRNA doses	18	19458	95 (92, 97)	98 (96, 99)	6	14424	87 (72, 94)	94 (87, 97)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	17	8077	88 (81, 93)	94 (90, 96)	13	16902	77 (60, 87)	94 (89, 97)
Two mixed ChAdOx1 + mRNA	2	14084	99 (97, 100)	99 (98, 100)	7	25728	92 (83, 96)	98 (95, 99)
Unvaccinated	1365	76621	Reference		702	212918	Reference	

VE=vaccine effectiveness; 95% CI = 95% confidence interval

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥ 80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

Supplementary Table 5. Two-dose vaccine effectiveness against infection (≥ 14 days post-vaccination), by age group and vaccine type, British Columbia and Quebec, Canada

	British Columbia				Quebec			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
18-49 years								
Two any vaccines	4693	145047	87 (87, 88)	89 (89, 90)	3007	283589	82 (81, 83)	89 (89, 90)
Two any mRNA vaccines	4171	134464	88 (87, 88)	90 (90, 90)	2922	277438	82 (82, 83)	89 (89, 90)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	3103	100530	88 (87, 88)	90 (89, 90)	2298	206318	81 (80, 82)	89 (88, 89)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	795	25637	88 (87, 89)	90 (89, 91)	527	62597	86 (85, 87)	91 (90, 92)
Two mixed mRNA doses	273	8292	87 (85, 88)	89 (88, 91)	97	8523	81 (77, 84)	89 (86, 91)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	250	2641	62 (57, 67)	68 (63, 72)	28	824	43 (17, 61)	68 (53, 78)
Two mixed ChAdOx1 + mRNA	272	7942	86 (85, 88)	89 (87, 90)	57	5327	82 (77, 86)	90 (87, 92)
Unvaccinated	14576	57847	Reference		9464	159076	Reference	
50-69 years								
Two any vaccines	2197	68407	87 (86, 88)	90 (89, 91)	1497	168612	77 (75, 78)	86 (85, 87)
Two any mRNA vaccines	1680	57041	88 (88, 89)	91 (91, 92)	1183	142701	78 (76, 80)	87 (86, 88)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	1205	39629	88 (87, 89)	91 (90, 91)	957	108114	77 (75, 78)	87 (85, 88)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	307	10770	89 (87, 90)	92 (91, 93)	200	31261	83 (80, 85)	89 (88, 91)
Two mixed mRNA doses	167	6640	90 (88, 91)	92 (91, 94)	26	3326	79 (70, 86)	88 (82, 92)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	388	5319	71 (67, 74)	73 (70, 76)	149	8889	56 (48, 63)	74 (69, 78)
Two mixed ChAdOx1 + mRNA	129	6047	91 (90, 93)	93 (91, 94)	165	17022	74 (70, 78)	87 (85, 89)
Unvaccinated	3463	13824	Reference		1645	43380	Reference	
≥ 70 years²								
Two any vaccines	754	38895	88 (86, 89)	91 (90, 92)	602	102682	76 (72, 79)	85 (82, 87)
Two any mRNA vaccines	744	38683	88 (86, 89)	91 (90, 92)	529	92114	77 (73, 80)	85 (82, 87)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	568	28672	87 (86, 89)	91 (90, 92)	452	73536	75 (71, 79)	84 (81, 86)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	107	5482	87 (85, 90)	93 (91, 94)	69	16003	82 (77, 87)	88 (84, 91)
Two mixed mRNA doses	69	4526	90 (87, 92)	93 (91, 95)	8	2575	87 (74, 94)	92 (83, 96)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	7	117	62 (17, 82)	73 (42, 88)	53	7189	70 (60, 78)	81 (74, 86)
Two mixed ChAdOx1 + mRNA	3	95	80 (36, 94)	85 (52, 95)	20	3379	76 (62, 85)	88 (81, 93)
Unvaccinated	770	4950	Reference		257	10462	Reference	
≥ 80 years								
Two any vaccines	221	14738	85 (81, 87)	89 (86, 91)	197	36296	68 (58, 75)	77 (70, 83)
Two any mRNA vaccines	219	14699	85 (82, 88)	89 (86, 91)	188	33974	67 (57, 75)	77 (70, 83)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	183	11030	83 (79, 86)	87 (84, 90)	157	27080	65 (54, 74)	76 (68, 82)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	21	2061	90 (84, 93)	93 (90, 96)	27	5875	73 (57, 82)	80 (68, 87)
Two mixed mRNA doses	15	1608	90 (84, 94)	93 (87, 96)	4	1019	77 (36, 91)	83 (52, 94)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	1	24	NE	NE	5	1733	83 (57, 93)	85 (62, 94)
Two mixed ChAdOx1 + mRNA	1	15	NE	NE	4	589	59 (-11, 85)	74 (29, 91)
Unvaccinated	205	2092	Reference		76	4534	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).² Among those ≥ 70 years, VE additionally adjusted for 70-79 and ≥ 80 years.

Supplementary Table 6. Two-dose vaccine effectiveness against hospitalization (≥ 14 days post-vaccination), by age group and vaccine type, British Columbia and Quebec, Canada

	British Columbia				Quebec			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
18-49 years²								
Two any vaccines	26	145047	98 (97, 99)	99 (98, 99)	28	283589	95 (93, 97)	97 (96, 98)
Two any mRNA vaccines	25	134464	98 (97, 99)	98 (98, 99)	28	277438	95 (93, 97)	97 (96, 98)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	13	100530	99 (98, 99)	99 (98, 99)	20	206318	95 (92, 97)	97 (96, 98)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	9	25637	96 (93, 98)	97 (95, 99)	7	62597	94 (88, 97)	96 (92, 98)
Two mixed mRNA doses	3	8292	96 (88, 99)	97 (91, 99)	1	8523	94 (58, 99)	97 (76, 100)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	1	2641	96 (72, 99)	97 (78, 100)	0	824	NE	NE
Two mixed ChAdOx1 + mRNA	0	7942	NE	NE	0	5327	NE	NE
Unvaccinated	558	57847		Reference	317	159076		Reference
50-69 years								
Two any vaccines	65	68407	97 (97, 98)	98 (97, 98)	38	168612	96 (95, 97)	98 (97, 99)
Two any mRNA vaccines	50	57041	98 (97, 98)	98 (98, 99)	29	142701	97 (95, 98)	98 (97, 99)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	31	39629	98 (97, 99)	98 (98, 99)	21	108114	97 (95, 98)	98 (97, 99)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	13	10770	97 (94, 98)	98 (96, 99)	6	31261	97 (93, 99)	98 (96, 99)
Two mixed mRNA doses	6	6640	98 (95, 99)	98 (96, 99)	2	3326	90 (61, 98)	95 (78, 99)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	14	5319	93 (88, 96)	94 (89, 96)	6	8889	89 (76, 95)	94 (87, 97)
Two mixed ChAdOx1 + mRNA	1	6047	100 (97, 100)	100 (97, 100)	3	17022	97 (91, 99)	99 (96, 100)
Unvaccinated	523	13824		Reference	271	43380		Reference
≥ 70 years^{3,4}								
Two any vaccines	106	38895	95 (94, 96)	97 (96, 97)	97	102682	91 (89, 93)	94 (93, 96)
Two any mRNA vaccines	103	38683	95 (94, 96)	97 (96, 97)	86	92114	91 (89, 94)	94 (93, 96)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	78	28672	95 (94, 96)	97 (95, 97)	72	73536	91 (88, 93)	94 (92, 96)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	16	5482	95 (92, 97)	97 (95, 98)	11	16003	94 (88, 97)	96 (92, 98)
Two mixed mRNA doses	9	4526	97 (93, 98)	97 (95, 99)	3	2575	89 (66, 97)	93 (77, 98)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	2	117	70 (-21, 93)	79 (14, 95)	7	7189	91 (81, 96)	94 (88, 97)
Two mixed ChAdOx1 + mRNA	1	95	82 (-32, 97)	86 (-2, 98)	4	3379	89 (71, 96)	95 (85, 98)
Unvaccinated	284	4950		Reference	114	10462		Reference
≥ 80 years⁵								
Two any vaccines	60	14738	91 (88, 94)	94 (91, 96)	52	36296	83 (75, 89)	88 (82, 92)
Two any mRNA vaccines	60	14699	91 (88, 94)	94 (91, 96)	47	33974	84 (75, 89)	89 (83, 93)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	45	11030	91 (88, 94)	94 (91, 96)	38	27080	84 (74, 90)	89 (82, 93)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	11	2061	89 (79, 94)	93 (86, 96)	7	5875	86 (69, 94)	90 (77, 96)
Two mixed mRNA doses	4	1608	95 (86, 98)	96 (89, 99)	2	1019	77 (5, 95)	82 (27, 96)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	0	24	NE	NE	3	1733	80 (35, 94)	82 (43, 95)
Two mixed ChAdOx1 + mRNA	0	15	NE	NE	2	589	NE	NE
Unvaccinated	98	2092		Reference	39	4534		Reference

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

² In Quebec, adjusted VE estimates against hospitalization in 18-49-year-olds were adjusted for calendar time bi-weekly owing to sample size.

³ Among those ≥ 70 years, VE additionally adjusted for 70-79 and ≥ 80 years in both provinces.

⁴ In Quebec, adjusted VE estimates against hospitalization in ≥ 70 -year-olds were adjusted for calendar time tri-weekly owing to sample size.

⁵ In Quebec, adjusted VE estimates against hospitalization in ≥ 80 -year-olds were adjusted for calendar time tri-weekly owing to sample size.

Supplementary Table 7. Two-dose vaccine effectiveness against infection and hospitalization (≥ 14 days post-vaccination), by sex and vaccine type, ≥ 18 -year-olds, British Columbia and Quebec, Canada

	British Columbia				Quebec			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Female, Infection								
Two any vaccines	4149	146358	87 (87, 88)	90 (89, 90)	2818	330058	80 (79, 80)	87 (86, 87)
Two any mRNA vaccines	3716	135160	88 (87, 88)	90 (89, 90)	2650	309456	79 (78, 80)	87 (86, 87)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	2733	100157	88 (87, 88)	90 (89, 90)	2112	237473	79 (78, 80)	86 (86, 87)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	695	23727	87 (86, 88)	90 (89, 91)	471	63990	82 (81, 84)	88 (87, 89)
Two mixed mRNA doses	287	11270	89 (87, 90)	91 (89, 92)	67	7993	80 (74, 84)	87 (83, 90)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	258	3724	69 (64, 73)	72 (68, 76)	83	8300	76 (70, 81)	74 (67, 79)
Two mixed ChAdOx1 + mRNA	175	7474	89 (88, 91)	91 (90, 92)	85	12302	83 (79, 87)	87 (84, 90)
Unvaccinated	8718	39296	Reference		5561	133526	Reference	
Female, Hospitalization								
Two any vaccines	84	146358	96 (95, 97)	98 (97, 98)	71	330058	90 (87, 92)	96 (95, 97)
Two any mRNA vaccines	76	135160	96 (95, 97)	98 (97, 98)	63	309456	91 (88, 93)	96 (95, 97)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	49	100157	97 (95, 97)	98 (97, 98)	50	237473	90 (87, 93)	96 (95, 97)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	21	23727	94 (90, 96)	96 (94, 98)	12	63990	92 (85, 95)	96 (93, 98)
Two mixed mRNA doses	6	11270	96 (92, 98)	98 (96, 99)	1	7993	94 (60, 99)	97 (82, 100)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	7	3724	87 (72, 94)	92 (83, 96)	3	8300	84 (49, 95)	95 (85, 99)
Two mixed ChAdOx1 + mRNA	1	7474	99 (93, 100)	99 (95, 100)	5	12302	82 (55, 92)	94 (85, 97)
Unvaccinated	555	39296	Reference		295	133526	Reference	
Male, Infection								
Two any vaccines	3495	105991	88 (87, 88)	90 (90, 90)	2288	224825	86 (85, 87)	90 (90, 91)
Two any mRNA vaccines	2879	95028	89 (88, 89)	91 (90, 91)	1984	202797	87 (86, 87)	91 (90, 91)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	2143	68674	88 (88, 89)	90 (90, 91)	1595	150495	86 (85, 86)	90 (89, 90)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	514	18162	90 (89, 90)	92 (91, 92)	325	45871	90 (89, 91)	93 (92, 93)
Two mixed mRNA doses	222	8188	90 (89, 91)	91 (90, 92)	64	6431	86 (83, 89)	90 (87, 92)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	387	4353	67 (63, 70)	70 (67, 74)	147	8602	77 (72, 80)	73 (68, 78)
Two mixed ChAdOx1 + mRNA	229	6610	87 (85, 89)	89 (88, 91)	157	13426	84 (81, 86)	87 (85, 89)
Unvaccinated	10091	37325	Reference		5805	79392	Reference	
Male, Hospitalization								
Two any vaccines	113	105991	95 (94, 96)	98 (97, 98)	92	224825	92 (90, 94)	97 (96, 98)
Two any mRNA vaccines	102	95028	95 (94, 96)	98 (97, 98)	80	202797	92 (90, 94)	97 (96, 98)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	73	68674	95 (94, 96)	98 (97, 98)	63	150495	92 (89, 94)	97 (96, 98)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	17	18162	96 (93, 97)	98 (96, 99)	12	45871	95 (91, 97)	97 (96, 99)
Two mixed mRNA doses	12	8188	93 (88, 96)	97 (95, 98)	5	6431	85 (63, 94)	93 (82, 97)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	10	4353	89 (80, 94)	95 (90, 97)	10	8602	77 (58, 88)	93 (88, 97)
Two mixed ChAdOx1 + mRNA	1	6610	99 (95, 100)	100 (97, 100)	2	13426	97 (88, 99)	99 (96, 100)
Unvaccinated	810	37325	Reference		407	79392	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥ 80 years); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

Supplementary Table 8. Two-dose vaccine effectiveness (VE) against infection and hospitalization (≥ 14 days post-vaccination), Alpha and Delta variants, by vaccine type ≥ 18 -year-olds, British Columbia and Quebec, Canada

	British Columbia				Quebec			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Delta Infection								
Two any vaccines	3911	252349	90 (89, 90)	91 (90, 91)	3422	554883	79 (78, 80)	89 (88, 89)
Two any mRNA vaccines	3320	230188	90 (90, 91)	91 (91, 92)	3093	512253	80 (79, 81)	89 (89, 90)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	2501	168831	90 (90, 91)	91 (91, 92)	2489	387968	78 (77, 79)	89 (88, 89)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	573	41889	91 (90, 92)	92 (91, 93)	517	109861	84 (83, 86)	91 (90, 92)
Two mixed mRNA doses	245	19458	92 (90, 93)	92 (91, 93)	87	14424	80 (75, 84)	89 (86, 91)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	375	8077	69 (66, 72)	70 (66, 73)	162	16902	68 (62, 73)	73 (69, 78)
Two mixed ChAdOx1 + mRNA	216	14084	90 (88, 91)	91 (89, 92)	167	25728	78 (75, 81)	88 (85, 89)
Unvaccinated	11500	76621	Reference		6349	212918	Reference	
Delta Hospitalization²								
Two any vaccines	124	252349	96 (95, 96)	98 (97, 98)	99	445235	91 (89, 93)	97 (96, 98)
Two any mRNA vaccines	108	230188	96 (95, 97)	98 (97, 98)	85	411947	96 (94, 96)	97 (97, 98)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	76	168831	96 (95, 97)	98 (97, 98)	70	310111	95 (94, 96)	97 (96, 98)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	24	41889	95 (92, 97)	97 (96, 98)	11	90108	97 (95, 99)	98 (96, 99)
Two mixed mRNA doses	8	19458	96 (93, 98)	98 (97, 99)	4	11728	93 (80, 97)	95 (86, 98)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	14	8077	85 (74, 91)	92 (86, 95)	9	11532	83 (67, 91)	94 (89, 97)
Two mixed ChAdOx1 + mRNA	2	14084	99 (95, 100)	99 (97, 100)	5	21756	95 (88, 98)	98 (94, 99)
Unvaccinated	873	76621	Reference		438	94254	Reference	
Alpha Infection³								
Two any vaccines	18	252349	99 (99, 100)	95 (93, 97)	47	554883	99 (98, 99)	97 (97, 98)
Two any mRNA vaccines	14	230188	99 (99, 100)	96 (93, 98)	42	512253	99 (99, 99)	98 (97, 98)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	10	168831	99 (99, 100)	96 (93, 98)	32	387968	99 (98, 99)	98 (97, 98)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	3	41889	99 (98, 100)	95 (85, 98)	9	109861	99 (98, 99)	97 (95, 99)
Two mixed mRNA doses	1	19458	99 (96, 100)	96 (73, 99)	1	14424	99 (93, 100)	98 (87, 100)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	4	8077	95 (86, 98)	74 (29, 90)	3	16902	98 (93, 99)	94 (80, 98)
Two mixed ChAdOx1 + mRNA	0	14084	NE	NE	2	25728	99 (96, 100)	98 (90, 99)
Unvaccinated	728	76621	Reference		1589	212918	Reference	
Alpha Hospitalization^{4,5}								
Two any vaccines	2	252349	99 (96, 100)	97 (88, 99)	4	477261	98 (93, 99)	97 (92, 99)
Two any mRNA vaccines	2	230188	99 (96, 100)	97 (87, 99)	4	439590	97 (93, 99)	97 (91, 99)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	2	168831	99 (94, 100)	96 (83, 99)	1	332460	99 (94, 100)	99 (93, 100)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	0	41889	NE	NE	3	94626	91 (71, 97)	87 (56, 96)
Two mixed mRNA doses	0	19458	NE	NE	0	12504	NE	NE
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	0	8077	NE	NE	0	15273	NE	NE
Two mixed ChAdOx1 + mRNA	0	14084	NE	NE	0	22398	NE	NE
Unvaccinated	65	76621	Reference		64	183043	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥ 80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

² In Quebec, VE against hospitalizations due to Delta variant assessed only between weeks 31-39 because no hospitalized Delta variant cases were identified prior to that period.

³ In BC, adjusted VE against Alpha infections adjusted for calendar time as individual epidemiological weeks 22-35, but regrouping weeks 36-39 together owing to sample size considerations.

⁴ In BC, adjusted VE against Alpha hospitalizations adjusted for calendar time as individual epidemiological week 22-33, regrouping weeks 34-39 owing to sample size considerations.

⁵ In Quebec, VE against Alpha hospitalizations assessed only between weeks 23-38, and adjusted for calendar time by four epidemiological week periods.

Supplementary Table 9. Two-dose vaccine effectiveness (VE) against infection and hospitalization (≥ 14 days post-vaccination), Gamma variant, by vaccine type, ≥ 18 -year-olds, British Columbia, Canada

	British Columbia			
	Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted
Gamma Infection¹				
Two any vaccines	32	252349	99 (98, 99)	93 (90, 95)
Two any mRNA vaccines	29	230188	99 (98, 99)	93 (90, 96)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	24	168831	98 (98, 99)	93 (89, 95)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	3	41889	99 (98, 100)	95 (85, 99)
Two mixed mRNA doses	2	19458	99 (96, 100)	94 (75, 99)
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	2	8077	97 (89, 99)	90 (61, 98)
Two mixed ChAdOx1 + mRNA	1	14084	99 (95, 100)	96 (70, 99)
Unvaccinated	708	76621		Reference
Gamma Hospitalization²				
Two any vaccines	4	252349	98 (93, 99)	95 (87, 98)
Two any mRNA vaccines	4	230188	97 (93, 99)	95 (85, 98)
Two BNT162b2 (mRNA) (Pfizer-BioNTech, Comirnaty)	3	168831	97 (91, 99)	95 (83, 99)
Two mRNA-1273 (mRNA) (Moderna, Spikevax)	0	41889	NE	NE
Two mixed mRNA doses	1	19458	92 (44, 99)	NE
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)	0	8077	NE	NE
Two mixed ChAdOx1 + mRNA	0	14084	NE	NE
Unvaccinated	51	76621		Reference

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ In BC, adjusted VE against Gamma infections adjusted for age group (18-49, 50-69, 70-79, ≥ 80 years); sex (male, female); and region of the province (5) and for calendar time as individual epidemiological weeks 22-35, but regrouping weeks 36-39 together owing to sample size considerations.

² In BC, adjusted VE against Gamma hospitalizations adjusted for age group (18-49, 50-69, 70-79, ≥ 80 years); sex (male, female); and region of the province (5) and for calendar time as individual epidemiological week 22-33, regrouping weeks 34-39 owing to sample size considerations.

Supplementary Table 10. Two-dose vaccine effectiveness (VE) against infection and hospitalization, by time since vaccination, (mRNA and ChAdOx1), ≥18-year-olds, British Columbia, and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Any two mRNA vaccines, Infection								
0-13 days (0-1 week)	940	22615	83 (82, 84)	75 (73, 77)	745	64574	78 (77, 80)	69 (67, 71)
14-27 days (2-3 weeks)	378	28148	95 (94, 95)	94 (93, 95)	324	72539	92 (91, 93)	91 (90, 92)
28-55 days (4-7 weeks, 2 nd month)	1614	70047	91 (90, 91)	92 (92, 92)	1234	162071	86 (85, 87)	89 (89, 90)
56-83 days (8-11 weeks, 3 rd month)	2261	74147	88 (87, 88)	90 (90, 91)	1743	156632	79 (78, 80)	87 (87, 88)
84-111 days (12-15 weeks, 4 th month)	1428	38993	85 (84, 86)	88 (87, 89)	941	80130	78 (76, 79)	85 (84, 86)
112-139 days (16-19 weeks, 5 th month)	350	8837	84 (82, 86)	85 (83, 87)	277	26489	80 (78, 83)	88 (86, 89)
140-167 days (20-23 weeks, 6 th month)	88	2376	85 (81, 88)	82 (77, 85)	87	12433	87 (84, 89)	91 (89, 93)
168-195 days (24-27 weeks, 7 th month)	130	2618	80 (76, 83)	84 (81, 86)	19	1394	74 (60, 84)	79 (67, 87)
196+ days (28+ weeks, 8 th + month)	346	5022	72 (69, 75)	77 (74, 79)	9	565	70 (42, 84)	80 (61, 90)
Unvaccinated	18809	76621		Reference	11366	212918		Reference
Any two mRNA vaccines, Hospitalization								
0-13 days (0-1 week)	20	22615	95 (92, 97)	93 (89, 95)	12	64574	94 (90, 97)	92 (86, 96)
14-27 days (2-3 weeks)	8	28148	98 (97, 99)	98 (96, 99)	16	72539	93 (89, 96)	93 (89, 96)
28-55 days (4-7 weeks, 2 nd month)	26	70047	98 (97, 99)	98 (98, 99)	26	162071	95 (93, 97)	97 (95, 98)
56-83 days (8-11 weeks, 3 rd month)	55	74147	96 (95, 97)	98 (97, 99)	41	156632	92 (89, 94)	97 (96, 98)
84-111 days (12-15 weeks, 4 th month)	67	38993	90 (88, 92)	97 (96, 97)	48	80130	82 (76, 86)	95 (94, 97)
112-139 days (16-19 weeks, 5 th month)	14	8837	91 (85, 95)	95 (92, 97)	9	26489	90 (80, 95)	96 (92, 98)
140-167 days (20-23 weeks, 6 th month)	3	2376	93 (78, 98)	93 (78, 98)	2	12433	95 (80, 99)	97 (89, 99)
168+ days (24+ weeks, 7 th + month)	5	7640	96 (91, 98)	97 (94, 99)	1	1959	84 (-10, 98)	95 (67, 99)
Unvaccinated	1365	76621		Reference	702	212918		Reference
Two ChAdOx1 vaccines, Infection								
0-13 days (0-1 week)	7	558	95 (89, 98)	80 (57, 91)	6	1924	94 (87, 97)	74 (42, 88)
14-27 days (2-3 weeks)	8	548	94 (88, 97)	79 (58, 90)	4	2185	97 (91, 99)	86 (62, 95)
28-55 days (4-7 weeks, 2 nd month)	77	1504	79 (74, 83)	74 (67, 79)	17	3970	92 (87, 95)	82 (70, 89)
56-83 days (8-11 weeks, 3 rd month)	248	2826	64 (59, 69)	73 (69, 76)	62	4313	73 (65, 79)	74 (67, 80)
84+ days (12+ weeks, 4 th + month)	312	3199	60 (55, 65)	69 (64, 72)	147	6434	57 (50, 64)	71 (65, 75)
Unvaccinated	18809	76621		Reference	11366	212918		Reference
Two ChAdOx1 vaccines, Hospitalization								
0-13 days (0-1 week)	0	558	NE	NE	1	1924	84 (-12, 98)	78 (-59, 97)
14-27 days (2-3 weeks)	0	548	NE	NE	0	2185	NE	NE
28-55 days (4-7 weeks, 2 nd month)	3	1504	89 (65, 96)	88 (62, 96)	0	3970	NE	NE
56-83 days (8-11 weeks, 3 rd month)	7	2826	86 (71, 93)	93 (86, 97)	3	4313	79 (34, 93)	94 (81, 98)
84+ days (12+ weeks, 4 th + month)	7	3199	88 (74, 94)	95 (89, 98)	10	6434	53 (12, 75)	93 (87, 96)
Unvaccinated	1365	76621		Reference	702	212918		Reference

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

Supplementary Table 11. Two-dose vaccine effectiveness (VE) against infection and hospitalization, by time since vaccination, (and mRNA vaccine type), ≥18-year-olds, British Columbia, and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two BNT162b2 (Pfizer-BioNTech), Infection								
0-13 days (0-1 week)	717	16156	82 (80, 83)	72 (70, 74)	616	48138	76 (74, 78)	66 (63, 68)
14-27 days (2-3 weeks)	302	20709	94 (93, 95)	93 (93, 94)	256	55110	91 (90, 92)	91 (90, 92)
28-55 days (4-7 weeks, 2 nd month)	1268	51929	90 (89, 91)	92 (91, 92)	989	124151	85 (84, 86)	89 (88, 90)
56-83 days (8-11 weeks, 3 rd month)	1667	53607	87 (87, 88)	90 (89, 90)	1358	116747	78 (77, 79)	87 (86, 88)
84-111 days (12-15 weeks, 4 th month)	1009	27629	85 (84, 86)	88 (87, 89)	767	60368	76 (74, 78)	84 (83, 85)
112-139 days (16-19 weeks, 5 th month)	234	6906	86 (84, 88)	86 (84, 88)	238	20682	78 (75, 81)	88 (86, 89)
140-167 days (20-23 weeks, 6 th month)	62	1811	86 (82, 89)	81 (75, 85)	76	9721	85 (82, 88)	91 (89, 93)
168-195 days (24-27 weeks, 7 th month)	104	2069	80 (75, 83)	83 (79, 86)	16	782	62 (37, 77)	75 (59, 85)
196+ days (28+ weeks, 8 th + month)	230	4171	78 (74, 80)	81 (78, 83)	7	407	68 (32, 85)	80 (59, 91)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two BNT162b2 (Pfizer-BioNTech), Hospitalization								
0-13 days (0-1 week)	14	16156	95 (92, 97)	93 (87, 96)	10	48138	94 (88, 97)	92 (84, 95)
14-27 days (2-3 weeks)	6	20709	98 (96, 99)	98 (95, 99)	11	55110	94 (89, 97)	94 (89, 97)
28-55 days (4-7 weeks, 2 nd month)	18	51929	98 (97, 99)	98 (98, 99)	20	124151	95 (92, 97)	97 (95, 98)
56-83 days (8-11 weeks, 3 rd month)	40	53607	96 (94, 97)	98 (97, 99)	29	116747	92 (89, 95)	98 (96, 98)
84-111 days (12-15 weeks, 4 th month)	47	27629	90 (87, 93)	97 (96, 98)	45	60368	77 (69, 83)	95 (93, 96)
112-139 days (16-19 weeks, 5 th month)	6	6906	95 (89, 98)	97 (94, 99)	7	20682	90 (78, 95)	96 (92, 98)
140-167 days (20-23 weeks, 6 th month)	2	1811	94 (75, 98)	92 (69, 98)	1	9721	97 (78, 100)	98 (89, 100)
168+ days (24+ weeks, 7 th + month)	3	6240	97 (92, 99)	98 (94, 99)	0	1189	NE	NE
Unvaccinated	1365	76621	Reference		702	212918	Reference	
Two mRNA-1273 (Moderna), Infection								
0-13 days (0-1 week)	199	4707	83 (80, 85)	81 (77, 83)	118	14125	84 (81, 87)	79 (75, 82)
14-27 days (2-3 weeks)	65	5512	95 (94, 96)	95 (94, 96)	63	15315	92 (90, 94)	92 (90, 94)
28-55 days (4-7 weeks, 2 nd month)	248	13052	92 (91, 93)	94 (93, 94)	212	33187	88 (86, 90)	91 (90, 92)
56-83 days (8-11 weeks, 3 rd month)	356	12943	89 (88, 90)	91 (90, 92)	312	34862	83 (81, 85)	90 (89, 91)
84-111 days (12-15 weeks, 4 th month)	261	6685	84 (82, 86)	88 (87, 90)	160	17915	83 (80, 86)	87 (85, 89)
112-139 days (16-19 weeks, 5 th month)	112	1749	74 (68, 78)	82 (78, 85)	35	5286	88 (83, 91)	87 (82, 91)
140-167 days (20-23 weeks, 6 th month)	25	558	82 (73, 88)	84 (76, 89)	9	2537	84 (81, 87)	79 (75, 82)
168+ days (24+ weeks, 7 th + month)	334	6240	58 (51, 65)	71 (65, 75)	5	759	88 (70, 95)	86 (67, 94)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two mRNA-1273 (Moderna), Hospitalization								
0-13 days (0-1 week)	6	4707	93 (84, 97)	91 (81, 96)	1	14125	98 (85, 100)	97 (79, 100)
14-27 days (2-3 weeks)	1	5512	99 (93, 100)	99 (92, 100)	3	15315	94 (82, 98)	94 (81, 98)
28-55 days (4-7 weeks, 2 nd month)	4	13052	98 (95, 99)	99 (96, 100)	5	33187	95 (89, 98)	97 (93, 99)
56-83 days (8-11 weeks, 3 rd month)	9	12943	96 (92, 98)	98 (96, 99)	9	34862	92 (85, 96)	97 (94, 98)
84-111 days (12-15 weeks, 4 th month)	13	6685	89 (81, 94)	96 (93, 98)	3	17915	95 (84, 98)	98 (94, 99)
112-139 days (16-19 weeks, 5 th month)	8	1749	74 (48, 87)	90 (79, 95)	2	5286	89 (54, 97)	93 (72, 98)
140-167 days (20-23 weeks, 6 th month)	1	558	90 (28, 99)	94 (56, 99)	1	2537	88 (15, 98)	92 (44, 99)
168+ days (24+ weeks, 7 th + month)	3	6240	92 (68, 98)	96 (83, 99)	1	759	NE	NE
Unvaccinated	1365	76621	Reference		702	212918	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

Supplementary Table 12. Two-dose vaccine effectiveness (VE) against infection and hospitalization, by time since vaccination, (mixed mRNA and mRNA/ChAdOx1), ≥18-year-olds, British Columbia, and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two mixed mRNA, Infection								
0-13 days (0-1 week)	24	1750	94 (92, 96)	83 (74, 89)	11	2311	91 (84, 95)	79 (61, 88)
14-27 days (2-3 weeks)	11	1925	98 (96, 99)	95 (91, 97)	5	2114	96 (89, 98)	93 (84, 97)
28-55 days (4-7 weeks, 2 nd month)	98	5064	92 (90, 94)	93 (91, 94)	33	4733	87 (82, 91)	90 (86, 93)
56-83 days (8-11 weeks, 3 rd month)	238	7594	87 (85, 89)	91 (89, 92)	73	5023	73 (66, 78)	85 (81, 88)
84-111 days (12-15 weeks, 4 th month)	157	4677	86 (84, 88)	88 (86, 90)	14	1847	86 (76, 92)	90 (83, 94)
112-139 days (16-19 weeks, 5 th month)	4	182	91 (76, 97)	93 (80, 97)	4	521	86 (61, 95)	91 (76, 97)
140-167 days (20-23 weeks, 6 th month)	1	7	NE	NE	2	175	79 (14, 95)	85 (40, 96)
168-195 days (24-27 weeks, 7 th month)	0	1	NE	NE	0	8	NE	NE
196+ days (28+ weeks, 8 th + month)	0	8	NE	NE	0	3	NE	NE
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two mixed mRNA, Hospitalization								
0-13 days (0-1 week)	0	1750	NE	NE	1	2311	87 (7, 98)	NE
14-27 days (2-3 weeks)	1	1925	97 (79, 100)	95 (64, 99)	2	2114	NE	NE
28-55 days (4-7 weeks, 2 nd month)	4	5064	96 (88, 98)	97 (92, 100)	1	4733	94 (54, 99)	96 (70, 99)
56-83 days (8-11 weeks, 3 rd month)	6	7594	96 (90, 98)	98 (96, 99)	3	5023	82 (44, 94)	93 (78, 98)
84-111 days (12-15 weeks, 4 th month)	7	4677	92 (82, 96)	97 (94, 99)	0	1847	NE	NE
112-139 days (16-19 weeks, 5 th month)	0	182	NE	NE	0	521	NE	NE
140-167 days (20-23 weeks, 6 th month)	0	7	NE	NE	0	175	NE	NE
168+ days (24+ weeks, 7 th + month)	0	1	NE	NE	0	8	NE	NE
Unvaccinated	1365	76621	Reference		702	212918	Reference	
Two mixed ChadOx1 + mRNA, Infection								
0-13 days (0-1 week)	39	950	83 (77, 88)	45 (23, 60)	11	3382	94 (89, 97)	78 (60, 88)
14-27 days (2-3 weeks)	11	1115	96 (93, 98)	93 (87, 96)	7	3363	96 (92, 98)	91 (82, 96)
28-55 days (4-7 weeks, 2 nd month)	102	3756	89 (87, 91)	91 (89, 92)	48	7334	88 (84, 91)	88 (84, 91)
56-83 days (8-11 weeks, 3 rd month)	176	5833	88 (86, 89)	91 (89, 92)	18	9694	77 (73, 81)	87 (84, 89)
84-111 days (12-15 weeks, 4 th month)	114	3335	86 (83, 88)	88 (86, 90)	68	5230	76 (69, 81)	84 (79, 87)
112-139 days (16-19 weeks, 5 th month)	1	45	91 (34, 99)	92 (44, 99)	0	101	NE	NE
140-167 days (20-23 weeks, 6 th month)	0	0	NE	NE	1	5	NE	NE
168+ days (24+ weeks, 7 th + month)	0	0	NE	NE	0	1	NE	NE
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two mixed ChadOx1 + mRNA, Hospitalization								
0-13 days (0-1 week)	0	950	NE	NE	0	3382	NE	NE
14-27 days (2-3 weeks)	1	1115	95 (64, 99)	91 (34, 99)	0	3363	NE	NE
28-55 days (4-7 weeks, 2 nd month)	1	3756	99 (89, 100)	99 (91, 100)	1	7334	96 (71, 99)	98 (87, 100)
56-83 days (8-11 weeks, 3 rd month)	0	5833	NE	NE	2	9694	94 (75, 98)	99 (94, 100)
84-111 days (12-15 weeks, 4 th month)	0	3335	NE	NE	4	5230	77 (38, 91)	94 (84, 98)
112-139 days (16-19 weeks, 5 th month)	0	45	NE	NE	0	101	NE	NE
140-167 days (20-23 weeks, 6 th month)	0	0	NE	NE	0	5	NE	NE
168+ days (24+ weeks, 7 th + month)	0	0	NE	NE	0	1	NE	NE
Unvaccinated	1365	76621	Reference		702	212918	212918	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

Supplementary Table 13. Two-dose vaccine effectiveness (VE) against Delta-specific infection and hospitalization, by time since vaccination, (mRNA and ChAdOx1), ≥18-year-olds, British Columbia, and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Any two mRNA vaccines, Delta infection								
0-13 days (0-1 week)	667	22615	80 (79, 82)	74 (72, 76)	322	64574	83 (81, 85)	73 (70, 76)
14-27 days (2-3 weeks)	260	28148	94 (93, 95)	95 (94, 95)	162	72539	93 (91, 94)	92 (91, 93)
28-55 days (4-7 weeks, 2 nd month)	1113	70047	89 (89, 90)	93 (92, 93)	744	162071	85 (83, 86)	90 (90, 91)
56-83 days (8-11 weeks, 3 rd month)	1136	74147	90 (89, 90)	91 (90, 91)	1223	156632	74 (72, 75)	88 (88, 89)
84-111 days (12-15 weeks, 4 th month)	464	38993	92 (91, 93)	89 (88, 90)	682	80130	71 (69, 74)	86 (85, 87)
112-139 days (16-19 weeks, 5 th month)	85	8837	94 (92, 95)	85 (81, 88)	199	26489	75 (71, 78)	89 (87, 90)
140-167 days (20-23 weeks, 6 th month)	41	2376	89 (84, 92)	80 (73, 86)	61	12433	84 (79, 87)	92 (90, 94)
168-195 days (24-27 weeks, 7 th month)	110	2618	72 (66, 77)	83 (80, 86)	14	1394	66 (43, 80)	79 (65, 88)
196+ days (28+ weeks, 8 th + month)	111	5022	85 (82, 88)	79 (75, 83)	8	565	53 (5, 76)	78 (55, 89)
Unvaccinated	11500	76621		Reference	6349	212918		Reference
Any two mRNA vaccines, Delta Hospitalization²								
0-13 days (0-1 week)	10	22615	96 (93, 98)	92 (86, 96)	5	19611	95 (87, 98)	93 (83, 97)
14-27 days (2-3 weeks)	5	28148	98 (96, 99)	98 (95, 99)	7	34394	96 (91, 98)	94 (88, 97)
28-55 days (4-7 weeks, 2 nd month)	17	70047	98 (97, 99)	99 (98, 99)	9	118284	98 (97, 99)	98 (97, 99)
56-83 days (8-11 weeks, 3 rd month)	46	74147	95 (93, 96)	98 (97, 98)	25	142975	96 (94, 97)	98 (97, 99)
84-111 days (12-15 weeks, 4 th month)	30	38993	93 (90, 95)	97 (96, 98)	36	76325	90 (86, 93)	96 (94, 97)
112-139 days (16-19 weeks, 5 th month)	7	8837	93 (85, 97)	93 (85, 97)	7	25841	94 (88, 97)	96 (91, 98)
140-167 days (20-23 weeks, 6 th month)	1	2376	96 (74, 99)	95 (65, 99)	1	12199	98 (87, 100)	98 (89, 100)
168+ days (24+ weeks, 7 th + month)	2	7640	98 (91, 99)	98 (93, 100)	0	1929	NE	NE
Unvaccinated	873	76621		Reference	438	94524		Reference
Two ChAdOx1 vaccines, Delta infection								
0-13 days (0-1 week)	2	558	98 (90, 99)	76 (1, 94)	0	1924	NE	NE
14-27 days (2-3 weeks)	4	548	95 (87, 98)	77 (38, 92)	2	2185	97 (88, 99)	74 (-7, 94)
28-55 days (4-7 weeks, 2 nd month)	74	1504	67 (59, 74)	68 (60, 75)	9	3970	92 (85, 96)	78 (58, 89)
56-83 days (8-11 weeks, 3 rd month)	199	2826	53 (46, 59)	72 (67, 76)	36	4313	72 (61, 80)	76 (67, 83)
84+ days (12+ weeks, 4 th + month)	98	3199	80 (75, 83)	65 (57, 72)	115	6434	40 (28, 50)	72 (66, 77)
Unvaccinated	11500	76621		Reference	6349	212918		Reference
Two ChAdOx1 vaccines, Delta Hospitalization²								
0-13 days (0-1 week)	0	558	NE	NE	0	68	NE	NE
14-27 days (2-3 weeks)	0	548	NE	NE	0	149	NE	NE
28-55 days (4-7 weeks, 2 nd month)	3	1504	82 (46, 94)	84 (51, 95)	0	989	NE	NE
56-83 days (8-11 weeks, 3 rd month)	6	2826	81 (58, 92)	93 (84, 97)	1	3962	95 (61, 99)	97 (78, 100)
84+ days (12+ weeks, 4 th + month)	5	3199	86 (67, 94)	92 (81, 97)	8	6432	73 (46, 87)	93 (86, 97)
Unvaccinated	873	76621		Reference	438	94524		Reference

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).² In Quebec, VE against hospitalizations due to Delta variant assessed only between weeks 31-39 because no hospitalized Delta variant cases identified prior to that period.

Supplementary Table 14. Two-dose vaccine effectiveness (VE) against Delta-specific infection and hospitalization, by time since vaccination, (and mRNA vaccine type), ≥18-year-olds, British Columbia, and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two BNT162b2 (Pfizer-BioNTech), Infection								
0-13 days (0-1 week)	517	16156	79 (77, 81)	71 (69, 74)	260	48138	82 (79, 84)	70 (66, 74)
14-27 days (2-3 weeks)	215	20709	93 (92, 94)	94 (93, 95)	131	55110	92 (91, 93)	92 (90, 93)
28-55 days (4-7 weeks, 2 nd month)	883	51929	89 (88, 89)	92 (92, 93)	598	124151	84 (82, 85)	90 (89, 91)
56-83 days (8-11 weeks, 3 rd month)	819	53607	90 (89, 91)	90 (90, 91)	956	116747	73 (71, 74)	88 (87, 89)
84-111 days (12-15 weeks, 4 th month)	330	27629	92 (91, 93)	89 (88, 90)	562	60368	69 (66, 71)	85 (84, 86)
112-139 days (16-19 weeks, 5 th month)	48	6906	95 (94, 97)	86 (81, 89)	171	20682	72 (68, 76)	89 (87, 90)
140-167 days (20-23 weeks, 6 th month)	34	1811	87 (82, 91)	77 (67, 84)	53	9721	82 (76, 86)	92 (89, 94)
168-195 days (24-27 weeks, 7 th month)	85	2069	73 (66, 78)	83 (79, 86)	11	782	53 (14, 74)	76 (57, 87)
196+ days (28+ weeks, 8 th + month)	87	4171	86 (83, 89)	80 (76, 84)	7	407	42 (-22, 73)	76 (48, 88)
Unvaccinated	11500	76621	Reference		6349	212918	Reference	
Two BNT162b2 (Pfizer-BioNTech), Hospitalization²								
0-13 days (0-1 week)	8	16156	96 (91, 98)	91 (82, 95)	3	14594	96 (86, 99)	94 (82, 98)
14-27 days (2-3 weeks)	4	20709	98 (95, 99)	98 (94, 99)	6	25973	95 (89, 98)	94 (86, 97)
28-55 days (4-7 weeks, 2 nd month)	12	51929	98 (96, 99)	99 (98, 99)	6	88853	99 (97, 99)	99 (97, 99)
56-83 days (8-11 weeks, 3 rd month)	34	53607	94 (92, 96)	98 (97, 98)	18	106378	96 (94, 98)	98 (97, 99)
84-111 days (12-15 weeks, 4 th month)	22	27629	93 (89, 95)	97 (96, 98)	34	57834	87 (82, 91)	95 (93, 97)
112-139 days (16-19 weeks, 5 th month)	1	6906	99 (91, 100)	98 (88, 100)	5	20332	95 (87, 98)	97 (92, 99)
140-167 days (20-23 weeks, 6 th month)	1	1811	95 (66, 99)	92 (41, 99)	1	9578	98 (84, 100)	98 (87, 100)
168+ days (24+ weeks, 7 th + month)	2	6240	97 (89, 99)	98 (91, 99)	0	1163	NE	NE
Unvaccinated	873	76621	Reference		438	94524	Reference	
Two mRNA-1273 (Moderna), Infection								
0-13 days (0-1 week)	140	4707	80 (77, 83)	80 (76, 83)	55	14125	87 (83, 90)	81 (76, 86)
14-27 days (2-3 weeks)	40	5512	95 (93, 96)	96 (94, 97)	29	15315	94 (91, 96)	94 (91, 96)
28-55 days (4-7 weeks, 2 nd month)	150	13052	92 (91, 93)	94 (93, 95)	123	33187	88 (85, 90)	92 (91, 93)
56-83 days (8-11 weeks, 3 rd month)	190	12943	90 (89, 92)	91 (90, 93)	216	34862	79 (76, 82)	91 (89, 92)
84-111 days (12-15 weeks, 4 th month)	100	6685	90 (88, 92)	88 (86, 90)	112	17915	79 (75, 83)	88 (86, 90)
112-139 days (16-19 weeks, 5 th month)	37	1749	86 (80, 90)	83 (76, 88)	25	5286	84 (76, 89)	87 (81, 91)
140-167 days (20-23 weeks, 6 th month)	7	558	92 (82, 96)	89 (76, 95)	8	2537	89 (79, 95)	91 (81, 95)
168+ days (24+ weeks, 7 th + month)	49	1390	77 (69, 82)	80 (73, 85)	4	759	82 (53, 93)	85 (61, 95)
Unvaccinated	11500	76621	Reference		6349	212918	Reference	
Two mRNA-1273 (Moderna), Hospitalization²								
0-13 days (0-1 week)	2	4707	96 (85, 99)	95 (80, 99)	1	4689	95 (67, 99)	94 (59, 99)
14-27 days (2-3 weeks)	1	5512	98 (89, 100)	98 (89, 100)	0	7620	NE	NE
28-55 days (4-7 weeks, 2 nd month)	2	13052	99 (95, 100)	99 (96, 100)	2	25763	98 (93, 100)	98 (93, 100)
56-83 days (8-11 weeks, 3 rd month)	8	12943	95 (89, 97)	98 (95, 99)	5	31846	97 (92, 99)	98 (95, 99)
84-111 days (12-15 weeks, 4 th month)	7	6685	91 (81, 96)	96 (92, 98)	2	16686	97 (90, 99)	99 (94, 100)
112-139 days (16-19 weeks, 5 th month)	6	1749	70 (33, 87)	84 (63, 93)	2	4990	91 (65, 98)	92 (66, 98)
140-167 days (20-23 weeks, 6 th month)	0	558	NE	NE	0	2448	NE	NE
168+ days (24+ weeks, 7 th + month)	0	1390	NE	NE	0	755	NE	NE
Unvaccinated	873	76621	Reference		438	94524	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

² In Quebec, VE against hospitalizations due to Delta variant assessed only between weeks 31-39 because no hospitalized Delta variant cases identified prior to that period.

Supplementary Table 15. Two-dose vaccine effectiveness (VE) against Delta-specific infection and hospitalization, by time since vaccination, (mixed mRNA and mRNA/ChAdOx1), ≥18-year-olds, British Columbia, and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two mixed mRNA, Delta Infection								
0-13 days (0-1 week)	10	1750	96 (93, 98)	85 (73, 92)	7	2311	90 (79, 95)	60 (16, 81)
14-27 days (2-3 weeks)	5	1925	98 (96, 99)	97 (92, 99)	2	2114	97 (87, 99)	94 (75, 98)
28-55 days (4-7 weeks, 2 nd month)	80	5064	89 (90, 92)	93 (91, 94)	23	4733	84 (75, 89)	89 (84, 93)
56-83 days (8-11 weeks, 3 rd month)	127	7594	89 (87, 91)	92 (90, 93)	51	5023	66 (55, 74)	87 (82, 90)
84-111 days (12-15 weeks, 4 th month)	33	4677	95 (93, 97)	88 (82, 91)	8	1847	85 (71, 93)	93 (86, 97)
112-139 days (16-19 weeks, 5 th month)	0	182	NE	NE	3	521	81 (40, 94)	91 (73, 97)
140-167 days (20-23 weeks, 6 th month)	0	7	NE	NE	0	175	NE	NE
168-195 days (24-27 weeks, 7 th month)	0	1	NE	NE	0	8	NE	NE
196+ days (28+ weeks, 8 th + month)		8	NE	NE	0	3	NE	NE
Unvaccinated	11500	76621	Reference		6349	212918	Reference	
Two mixed mRNA, Delta Hospitalization²								
0-13 days (0-1 week)	0	1750	NE	NE	1	328	NE	NE
14-27 days (2-3 weeks)	0	1925	NE	NE	1	801	NE	NE
28-55 days (4-7 weeks, 2 nd month)	3	5064	95 (84, 98)	96 (88, 99)	1	3668	94 (58, 99)	94 (55, 99)
56-83 days (8-11 weeks, 3 rd month)	4	7594	95 (88, 98)	98 (94, 99)	2	4751	91 (64, 98)	94 (77, 99)
84-111 days (12-15 weeks, 4 th month)	1	4677	98 (87, 100)	98 (85, 100)	0	1805	NE	NE
112-139 days (16-19 weeks, 5 th month)	0	182	NE	NE	0	519	NE	NE
140-167 days (20-23 weeks, 6 th month)	0	7	NE	NE	0	173	NE	NE
168+ days (24+ weeks, 7 th + month)	0	1	NE	NE	0	11	NE	NE
Unvaccinated	873	76621	Reference		438	94524	Reference	
Two mixed ChadOx1 + mRNA, Delta Infection								
0-13 days (0-1 week)	9	950	94 (88, 97)	73 (48, 86)	2	3382	98 (92, 100)	86 (42, 96)
14-27 days (2-3 weeks)	8	1115	95 (90, 98)	94 (87, 97)	4	3363	96 (89, 99)	87 (66, 95)
28-55 days (4-7 weeks, 2 nd month)	89	3756	84 (80, 87)	90 (88, 92)	27	7334	88 (82, 92)	89 (84, 92)
56-83 days (8-11 weeks, 3 rd month)	97	5833	89 (86, 91)	91 (89, 93)	85	9694	71 (64, 76)	88 (85, 90)
84-111 days (12-15 weeks, 4 th month)	22	3335	96 (93, 97)	85 (77, 90)	50	5230	68 (58, 76)	86 (81, 89)
112-139 days (16-19 weeks, 5 th month)	0	45	NE	NE	0	101	NE	NE
140-167 days (20-23 weeks, 6 th month)	0	0	NE	NE	0	5	NE	NE
168+ days (24+ weeks, 7 th + month)	0	0	NE	NE	0	1	NE	NE
Unvaccinated	11500	76621	Reference		6349	212918	Reference	
Two mixed ChadOx1 + mRNA, Delta Hospitalization²								
0-13 days (0-1 week)	0	950	NE	NE	0	310	NE	NE
14-27 days (2-3 weeks)	1	1115	92 (44, 99)	NE	0	795	NE	NE
28-55 days (4-7 weeks, 2 nd month)	1	3756	98 (83, 100)	99 (90, 100)	1	5957	96 (74, 99)	97 (81, 100)
56-83 days (8-11 weeks, 3 rd month)	0	5833	NE	NE	1	9669	88 (62, 96)	95 (85, 98)
84-111 days (12-15 weeks, 4 th month)	0	3335	NE	NE	3	5228	NE	NE
112-139 days (16-19 weeks, 5 th month)	0	45	NE	NE	0	101	NE	NE
140-167 days (20-23 weeks, 6 th month)	0	0	NE	NE	0	5	NE	NE
168+ days (24+ weeks, 7 th + month)	0	0	NE	NE	0	1	NE	NE
Unvaccinated	873	76621	Reference		438	94524	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).² In Quebec, VE against hospitalizations due to Delta variant assessed only between weeks 31-39 because no hospitalized Delta variant cases identified prior to that period.

Supplementary Table 16. Two-dose vaccine effectiveness against infection and hospitalization, by time since vaccination, (and mRNA vaccine type), ≥70-year-olds, British Columbia and Quebec, Canada

	British Columbia (BC), Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two any mRNA, Infection								
0-13 days (0-1 week)	38	4364	94 (92, 96)	81 (72, 87)	36	12080	88 (83, 91)	58 (37, 72)
14-27 days (2-3 weeks)	3	4438	100 (99, 100)	99 (96, 100)	19	13312	94 (91, 96)	83 (72, 90)
28-55 days (4-7 weeks, 2 nd month)	79	9556	95 (93, 96)	92 (89, 93)	74	26101	88 (85, 91)	85 (80, 89)
56-83 days (8-11 weeks, 3 rd month)	268	12123	86 (84, 88)	92 (91, 93)	158	26853	76 (71, 80)	88 (85, 90)
84-111 days (12-15 weeks, 4 th month)	311	10711	81 (79, 84)	91 (90, 92)	235	21499	56 (47, 63)	83 (79, 86)
112-139 days (16-19 weeks, 5 th month)	48	1453	79 (71, 84)	89 (85, 92)	30	3144	61 (43, 73)	82 (74, 88)
140+ (20+ weeks, 6 th + month)	35	402	44 (20, 61)	73 (60, 81)	13	1205	56 (23, 75)	76 (57, 87)
Unvaccinated	770	4950	Reference		257	10462	Reference	
Two any mRNA, Hospitalizations								
0-13 days (0-1 week)	6	4364	98 (95, 99)	92 (80, 97)	7	12080	95 (89, 98)	77 (47, 90)
14-27 days (2-3 weeks)	1	4438	100 (97, 100)	99 (91, 100)	4	13312	97 (93, 99)	92 (76, 97)
28-55 days (4-7 weeks, 2 nd month)	11	9556	98 (96, 99)	97 (94, 98)	12	26101	96 (92, 98)	94 (89, 97)
56-83 days (8-11 weeks, 3 rd month)	32	12123	95 (93, 97)	97 (96, 98)	28	26853	90 (86, 94)	95 (93, 97)
84-111 days (12-15 weeks, 4 th month)	48	10711	92 (89, 94)	96 (95, 97)	36	21499	85 (78, 89)	95 (92, 96)
112-139 days (16-19 weeks, 5 th month)	10	1453	88 (77, 94)	92 (85, 96)	5	3144	85 (64, 94)	94 (85, 98)
140+ days (20+ weeks, 6 th + month)	1	402	96 (69, 99)	98 (83, 100)	1	1205	92 (45, 99)	NE
Unvaccinated	284	4950	Reference		114	10462	10462	
Two BNT162b2 (Pfizer-BioNTech), Infection								
0-13 days (0-1 week)	30	3219	94 (91, 96)	79 (68, 86)	30	9593	87 (81, 91)	56 (31, 72)
14-27 days (2-3 weeks)	2	3253	100 (98, 100)	99 (94, 100)	17	10725	94 (89, 96)	80 (66, 88)
28-55 days (4-7 weeks, 2 nd month)	60	7072	95 (93, 96)	91 (88, 93)	63	20789	88 (84, 91)	84 (78, 88)
56-83 days (8-11 weeks, 3 rd month)	213	8904	85 (82, 87)	91 (89, 92)	127	21438	76 (70, 81)	88 (85, 90)
84-111 days (12-15 weeks, 4 th month)	243	8057	81 (7, 83)	91 (89, 92)	207	17733	52 (43, 60)	82 (77, 85)
112-139 days (16-19 weeks, 5 th month)	32	1123	82 (74, 87)	91 (86, 94)	27	2229	51 (27, 67)	80 (69, 87)
140+ (20+ weeks, 6 th + month)	18	263	56 (29, 73)	72 (54, 83)	11	622	28 (-32, 61)	68 (40, 83)
Unvaccinated	770	4950	Reference		257	10462	Reference	
Two BNT162b2 (Pfizer-BioNTech), Hospitalization²								
0-13 days (0-1 week)	5	3219	97 (93, 99)	91 (76, 96)	6	9593	94 (87, 97)	75 (38, 90)
14-27 days (2-3 weeks)	1	3253	99 (96, 100)	98 (86, 100)	3	10725	97 (92, 99)	92 (72, 97)
28-55 days (4-7 weeks, 2 nd month)	9	7072	98 (96, 99)	96 (93, 98)	10	20789	96 (92, 98)	94 (88, 97)
56-83 days (8-11 weeks, 3 rd month)	26	8904	95 (92, 97)	97 (96, 98)	21	21438	91 (86, 94)	95 (93, 97)
84-111 days (12-15 weeks, 4 th month)	37	8057	92 (89, 94)	96 (94, 97)	34	17733	82 (74, 88)	94 (91, 96)
112-139 days (16-19 weeks, 5 th month)	4	1123	94 (83, 98)	96 (89, 99)	4	2229	84 (55, 94)	94 (84, 98)
140+ days (20+ weeks, 6 th + month)	1	263	96 (69, 99)	98 (83, 100)	0	622	NE	NE
Unvaccinated	284	4950	Reference		114	10462	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

² In Quebec, adjusted VE estimates against hospitalization in ≥70-year-olds were adjusted for calendar time tri-weekly owing to sample size.

Supplementary Table 16 Contin'd. Two-dose vaccine effectiveness against infection and hospitalization, by time since vaccination, (and mRNA vaccine type), ≥70-year-olds, British Columbia and Quebec, Canada

	British Columbia (BC), Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two mRNA-1273 (Moderna), Infection								
0-13 days (0-1 week)	6	577	93 (85, 97)	85 (66, 94)	2	1996	96 (84, 99)	87 (48, 97)
14-27 days (2-3 weeks)	0	606	NE	NE	2	2149	96 (85, 99)	90 (59, 98)
28-55 days (4-7 weeks, 2 nd month)	8	1342	96 (92, 98)	96 (91, 98)	9	4520	92 (84, 96)	90 (80, 95)
56-83 days (8-11 weeks, 3 rd month)	27	1630	89 (84, 93)	94 (92, 96)	26	4683	77 (66, 85)	89 (83, 93)
84-111 days (12-15 weeks, 4 th month)	39	1488	83 (77, 88)	93 (90, 95)	27	3282	67 (50, 78)	85 (78, 90)
112-139 days (16-19 weeks, 5 th month)	16	278	63 (38, 78)	85 (75, 91)	3	800	85 (52, 95)	90 (67, 97)
140+ (20+ weeks, 6 th + month)	17	138	21 (-32, 52)	72 (51, 84)	2	569	86 (42, 96)	90 (59, 98)
Unvaccinated	770	4950	Reference		257	10462	Reference	
Two mRNA-1273 (Moderna), Hospitalization²								
0-13 days (0-1 week)	1	577	97 (78, 100)	93 (47, 99)	0	1996	NE	NE
14-27 days (2-3 weeks)	0	606	NE	NE	1	2149	96 (69, 99)	89 (17, 98)
28-55 days (4-7 weeks, 2 nd month)	0	1342	NE	NE	1	4520	98 (85, 100)	97 (81, 100)
56-83 days (8-11 weeks, 3 rd month)	3	1630	97 (90, 99)	98 (95, 99)	5	4683	90 (76, 96)	NE
84-111 days (12-15 weeks, 4 th month)	7	1488	92 (83, 96)	96 (92, 98)	2	3282	94 (77, 99)	NE
112-139 days (16-19 weeks, 5 th month)	6	278	62 (15, 83)	81 (56, 92)	1	800	89 (18, 98)	93 (45, 99)
140+ days (20+ weeks, 6 th + month)	0	138	NE	NE	1	569	84 (-16, 98)	NE
Unvaccinated	284	4950	Reference		114	10462	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (70-79, ≥80 years); sex (male, female); individual epidemiological week of the analysis period (weeks 22-39, categorical); and region of the province (5 in each province).

² In Quebec, adjusted VE estimates against hospitalization in ≥70-year-olds were adjusted for calendar time tri-weekly owing to sample size.

Supplementary Table 17. Two-dose vaccine effectiveness against infection and hospitalization (≥ 14 days post-vaccination), by interval between doses, (mRNA and ChAdOx1), ≥ 18 -year-olds, British Columbia and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Any two mRNA vaccines, Infection								
21-34 days (3-4 weeks)	211	4854	82 (80, 85)	85 (83, 87)	323	17679	66 (62, 69)	79 (76, 81)
35-48 days (5-6 weeks)	662	15844	83 (82, 84)	85 (83, 86)	419	30195	74 (71, 76)	85 (84, 87)
49-62 days (7-8 weeks)	2509	86580	88 (88, 89)	91 (91, 91)	1361	124758	80 (78, 81)	89 (88, 89)
63-83 days (9-11 weeks)	2049	81384	90 (89, 90)	91 (91, 91)	1355	159120	84 (83, 85)	89 (89, 90)
84-111 days (12-15 weeks)	1038	36602	88 (88, 89)	88 (88, 89)	735	109238	87 (86, 88)	89 (88, 90)
112+ days (16+ weeks)	126	4924	90 (88, 91)	91 (89, 92)	441	71263	88 (87, 89)	90 (89, 91)
49+ days (7+ weeks)	5722	209490	89 (89, 89)	91 (90, 91)	3892	464379	84 (84, 85)	89 (89, 90)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Any two mRNA vaccines, Hospitalization								
21-34 days (3-4 weeks)	9	4854	90 (80, 95)	93 (87, 96)	15	17679	74 (57, 85)	87 (79, 92)
35-48 days (5-6 weeks)	11	15844	96 (93, 98)	97 (94, 98)	5	30195	95 (88, 98)	97 (93, 99)
49-62 days (7-8 weeks)	24	86580	98 (98, 99)	99 (98, 99)	12	124758	97 (95, 98)	98 (97, 99)
63-83 days (9-11 weeks)	59	81384	96 (95, 97)	98 (98, 99)	38	159120	93 (90, 95)	97 (96, 98)
84-111 days (12-15 weeks)	66	36602	90 (87, 92)	95 (94, 96)	43	109238	88 (84, 91)	96 (95, 97)
112+ days (16+ weeks)	9	4924	90 (80, 95)	94 (89, 97)	30	71263	87 (82, 91)	95 (93, 97)
49+ days (7+ weeks)	158	209490	96 (95, 96)	98 (97, 98)	123	464379	92 (90, 93)	97 (96, 97)
Unvaccinated	1365	76621	Reference		702	212918	Reference	
Two ChAdOx1 vaccines, Infection								
21-34 days (3-4 weeks)	7	46	38 (-37, 72)	47 (-19, 76)	6	165	32 (-54, 70)	47 (-22, 77)
35-48 days (5-6 weeks)	25	293	65 (48, 77)	73 (60, 82)	19	734	52 (24, 69)	61 (39, 76)
49-62 days (7-8 weeks)	307	4170	70 (66, 73)	74 (70, 77)	82	4390	65 (56, 72)	69 (62, 76)
63-83 days (9-11 weeks)	261	3139	66 (62, 70)	69 (65, 73)	101	9174	79 (75, 83)	76 (70, 80)
84+ days (12+ weeks)	45	429	57 (42, 69)	62 (48, 72)	22	2439	83 (74, 89)	82 (73, 88)
49+ days (7+ weeks)	613	7738	68 (65, 70)	71 (69, 74)	205	16003	76 (72, 79)	75 (71, 78)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two ChAdOx1 vaccines, Hospitalization								
21-34 days (3-4 weeks)	0	46	NE	NE	1	165	NE	NE
35-48 days (5-6 weeks)	0	293	NE	NE	0	734	NE	NE
49-62 days (7-8 weeks)	10	4170	87 (75, 93)	93 (86, 96)	2	4390	86 (45, 97)	96 (83, 99)
63-83 days (9-11 weeks)	6	3139	89 (76, 95)	95 (89, 98)	7	9174	77 (51, 89)	94 (88, 97)
84+ days (12+ weeks)	1	429	87 (7, 98)	91 (34, 99)	3	2439	63 (-16, 88)	91 (73, 97)
49+ days (7+ weeks)	17	7738	88 (80, 92)	94 (90, 96)	12	16003	77 (60, 87)	94 (90, 97)
Unvaccinated	1365	76621	Reference		702	212918	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, 80+ years); sex (male, female); individual epidemiological week (22-39); and region of the province.

Supplementary Table 18. Two-dose vaccine effectiveness against infection and hospitalization (≥ 14 days post-vaccination), by interval between doses, (and mRNA vaccine type), ≥ 18 -year-olds, British Columbia and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two BNT162b2 (Pfizer-BioNTech) vaccines, Infection								
21-34 days (3-4 weeks)	133	3094	82 (79, 85)	85 (82, 87)	233	10384	58 (52, 63)	74 (71, 78)
35-48 days (5-6 weeks)	450	11113	84 (82, 85)	84 (83, 86)	266	17651	72 (68, 75)	85 (83, 86)
49-62 days (7-8 weeks)	1907	62727	88 (87, 88)	91 (90, 91)	1080	90646	78 (76, 79)	88 (87, 89)
63-83 days (9-11 weeks)	1527	59605	90 (89, 90)	91 (90, 91)	1099	119473	83 (82, 84)	89 (88, 89)
84-111 days (12-15 weeks)	762	28435	89 (88, 90)	89 (88, 90)	622	86829	87 (85, 88)	89 (88, 89)
112+ days (16+ weeks)	97	3857	90 (87, 92)	91 (88, 92)	407	62985	88 (87, 89)	90 (89, 91)
49+ days (7+ weeks)	4293	154624	89 (88, 89)	91 (90, 91)	3208	359933	83 (83, 84)	89 (88, 89)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two BNT162b2 (Pfizer-BioNTech) vaccines, Hospitalization								
21-34 days (3-4 weeks)	4	3094	93 (81, 97)	95 (86, 98)	6	10384	82 (61, 92)	92 (82, 96)
35-48 days (5-6 weeks)	4	11113	98 (95, 99)	98 (95, 99)	4	17651	93 (82, 97)	96 (89, 99)
49-62 days (7-8 weeks)	18	62727	98 (97, 99)	99 (98, 99)	9	90646	97 (94, 98)	98 (97, 99)
63-83 days (9-11 weeks)	42	59605	96 (95, 97)	98 (98, 99)	34	119473	91 (88, 94)	97 (95, 98)
84-111 days (12-15 weeks)	47	28435	91 (88, 93)	95 (93, 96)	36	86829	87 (82, 91)	96 (94, 97)
112+ days (16+ weeks)	7	3857	90 (79, 95)	94 (88, 97)	24	62985	88 (83, 92)	96 (93, 97)
49+ days (7+ weeks)	114	154624	96 (95, 97)	98 (97, 98)	103	359933	91 (89, 93)	97 (96, 97)
Unvaccinated	1365	76621	Reference		702	212918	Reference	
Two mRNA-1273 (Moderna) vaccines, Infection								
21-34 days (3-4 weeks)	65	1565	83 (78, 87)	87 (84, 90)	75	6531	78 (73, 83)	86 (82, 89)
35-48 days (5-6 weeks)	182	3935	81 (78, 84)	85 (82, 87)	125	10376	77 (73, 81)	87 (84, 89)
49-62 days (7-8 weeks)	384	16484	91 (89, 91)	92 (92, 93)	245	29984	85 (83, 87)	91 (90, 92)
63-83 days (9-11 weeks)	339	14137	90 (89, 91)	92 (91, 93)	227	35943	88 (87, 90)	91 (90, 92)
84-111 days (12-15 weeks)	218	5047	82 (80, 85)	86 (84, 88)	98	19989	91 (89, 92)	90 (88, 92)
112+ days (16+ weeks)	21	721	88 (82, 92)	91 (86, 94)	26	7038	93 (90, 95)	92 (89, 95)
49+ days (7+ weeks)	962	36389	89 (88, 90)	91 (91, 92)	596	92954	88 (87, 89)	91 (90, 92)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two mRNA-1273 (Moderna) vaccines, Hospitalization								
21-34 days (3-4 weeks)	4	1565	86 (62, 95)	91 (77, 97)	7	6531	67 (32, 85)	82 (63, 92)
35-48 days (5-6 weeks)	7	3935	90 (79, 95)	93 (85, 97)	1	10376	97 (79, 100)	98 (87, 100)
49-62 days (7-8 weeks)	2	16484	99 (97, 100)	100 (98, 100)	2	29984	98 (92, 99)	99 (95, 100)
63-83 days (9-11 weeks)	10	14137	96 (93, 98)	98 (97, 99)	4	35943	97 (91, 99)	98 (96, 99)
84-111 days (12-15 weeks)	14	5047	84 (74, 91)	94 (90, 96)	6	19989	91 (80, 96)	96 (92, 98)
112+ days (16+ weeks)	1	721	92 (45, 99)	97 (76, 100)	4	7038	83 (54, 94)	95 (86, 98)
49+ days (7+ weeks)	27	36389	96 (94, 97)	98 (97, 98)	16	92954	95 (91, 97)	98 (96, 99)
Unvaccinated	1365	76621	Reference		702	212918	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, 80+ years); sex (male, female); individual epidemiological week (22-39); and region of the province.

Supplementary Table 19. Two-dose vaccine effectiveness against infection, by interval between doses and time since second dose, by vaccine type, ≥18-year-olds, British Columbia and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two mRNA vaccines								
14-27 days (2-3 weeks) since second dose								
21-34 day (3-4 week) interval between doses	28	902	87 (82, 91)	90 (85, 93)	45	4099	79 (72, 85)	87 (82, 90)
35-48 day (5-6 week) interval between doses	30	1391	91 (87, 94)	93 (90, 95)	27	4675	89 (84, 93)	89 (84, 92)
49-62 day (7+ week) interval between doses	320	25855	95 (94, 95)	94 (94, 95)	252	63765	93 (92, 93)	92 (91, 93)
28-55 days (4-7 weeks) since second dose								
21-34 day (3-4 week) interval between doses	35	1068	87 (81, 90)	89 (84, 92)	95	5166	65 (58, 72)	78 (74, 82)
35-48 day (5-6 week) interval between doses	67	2232	88 (84, 90)	91 (88, 93)	133	9720	74 (70, 78)	85 (82, 88)
49-62 day (7+ week) interval between doses	1512	66747	91 (90, 91)	92 (92, 93)	1006	147185	87 (86, 88)	91 (90, 91)
56-83 days (8-11 weeks) since second dose								
21-34 day (3-4 week) interval between doses	30	698	82 (75, 88)	85 (78, 90)	81	3329	54 (43, 63)	74 (68, 79)
35-48 day (5-6 week) interval between doses	58	1421	83 (78, 87)	89 (85, 91)	179	10893	69 (64, 73)	86 (84, 88)
49-62 day (7+ week) interval between doses	2173	72028	88 (87, 88)	90 (90, 91)	1483	142410	80 (79, 82)	88 (88, 89)
84-111 days (12-15 weeks) since second dose								
21-34 day (3-4 week) interval between doses	36	719	80 (71, 85)	84 (77, 88)	62	2221	48 (33, 59)	70 (62, 77)
35-48 day (5-6 week) interval between doses	48	1393	86 (81, 89)	85 (81, 89)	55	3425	70 (61, 77)	85 (80, 88)
49-62 day (7+ week) interval between doses	1344	36881	85 (84, 86)	88 (87, 89)	824	74484	79 (78, 81)	86 (85, 87)
112+ days (16+ weeks) since second dose								
21-34 day (3-4 week) interval between doses	82	1467	77 (72, 82)	81 (76, 85)	40	2864	74 (64, 81)	81 (74, 86)
35-48 day (5-6 week) interval between doses	459	9407	80 (78, 82)	80 (78, 82)	25	1482	68 (53, 79)	78 (68, 85)
49-62 day (7+ week) interval between doses	373	7979	81 (79, 83)	84 (82, 86)	327	36535	83 (81, 85)	90 (88, 91)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two BNT162b2 (Pfizer-BioNTech, Comirnaty)								
14-27 days (2-3 weeks) since second dose								
21-34 day (3-4 week) interval between doses	14	452	87 (79, 93)	89 (82, 94)	35	2532	74 (64, 81)	83 (77, 88)
35-48 day (5-6 week) interval between doses	18	631	88 (81, 93)	90 (84, 94)	18	2799	88 (81, 92)	88 (80, 92)
49-62 day (7+ week) interval between doses	270	19626	94 (94, 95)	94 (93, 94)	203	49779	92 (91, 93)	92 (91, 93)
28-55 days (4-7 weeks) since second dose								
21-34 day (3-4 week) interval between doses	22	575	84 (76, 90)	86 (78, 91)	66	2870	57 (45, 66)	73 (66, 79)
35-48 day (5-6 week) interval between doses	39	1019	84 (79, 89)	88 (83, 91)	91	5873	71 (64, 76)	84 (80, 87)
49-62 day (7+ week) interval between doses	1207	50335	90 (90, 91)	92 (91, 92)	832	115408	86 (86, 87)	90 (89, 91)
56-83 days (8-11 weeks) since second dose								
21-34 day (3-4 week) interval between doses	21	488	82 (73, 89)	85 (76, 90)	56	2007	48 (32, 60)	72 (63, 78)
35-48 day (5-6 week) interval between doses	35	819	83 (76, 88)	88 (83, 92)	108	6588	69 (63, 75)	86 (83, 89)
49-62 day (7+ week) interval between doses	1611	52300	87 (87, 88)	90 (89, 91)	1194	108152	79 (78, 81)	88 (87, 88)
84-111 days (12-15 weeks) since second dose								
21-34 day (3-4 week) interval between doses	24	512	81 (71, 87)	85 (77, 90)	48	1285	30 (7, 48)	63 (50, 72)
35-48 day (5-6 week) interval between doses	29	956	88 (82, 91)	86 (79, 90)	35	1818	64 (50, 74)	82 (75, 87)
49-62 day (7+ week) interval between doses	956	26161	85 (84, 86)	88 (87, 89)	684	57265	78 (76, 79)	85 (84, 86)
112+ days (16+ weeks) since second dose								
21-34 day (3-4 week) interval between doses	52	1067	80 (74, 85)	82 (76, 87)	28	1690	69 (55, 79)	78 (68, 85)
35-48 day (5-6 week) interval between doses	329	7688	83 (81, 84)	82 (80, 84)	14	573	54 (22, 73)	73 (54, 84)
49-62 day (7+ week) interval between doses	249	6202	84 (81, 86)	85 (83, 87)	295	29329	81 (79, 83)	90 (88, 91)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, 80+ years); sex (male, female); individual epidemiological week (22-39); and region of the province.

Supplementary Table 19 Cont'd. Two-dose vaccine effectiveness against infection, by interval between doses and time since second dose, by vaccine type, ≥18-year-olds, British Columbia and Quebec, Canada

	British Columbia, Canada				Quebec, Canada			
	Sample sizes		VE (95% CI)		Sample sizes		VE (95% CI)	
	Case N	Control N	Crude	Adjusted ¹	Case N	Control N	Crude	Adjusted ¹
Two mRNA-1273 (Moderna, Spikevax)								
14-27 days (2-3 weeks) since second dose								
21-34 day (3-4 week) interval between doses	13	413	87 (78, 93)	91 (84, 95)	8	1430	90 (79, 95)	93 (87, 97)
35-48 day (5-6 week) interval between doses	11	660	93 (88, 96)	95 (91, 97)	9	1546	89 (79, 94)	90 (80, 95)
49-62 day (7+ week) interval between doses	41	4439	96 (95, 97)	96 (94, 97)	46	12339	93 (91, 95)	92 (90, 94)
28-55 days (4-7 weeks) since second dose								
21-34 day (3-4 week) interval between doses	11	440	90 (81, 94)	92 (86, 96)	25	2034	77 (66, 84)	86 (79, 90)
35-48 day (5-6 week) interval between doses	21	980	91 (87, 94)	93 (90, 96)	34	3167	80 (72, 86)	88 (83, 91)
49-62 day (7+ week) interval between doses	216	11632	92 (91, 93)	94 (93, 94)	153	27986	90 (88, 91)	92 (91, 94)
56-83 days (8-11 weeks) since second dose								
21-34 day (3-4 week) interval between doses	3	149	92 (74, 97)	92 (76, 98)	19	1110	68 (49, 80)	79 (67, 87)
35-48 day (5-6 week) interval between doses	7	305	91 (80, 96)	93 (86, 97)	52	3423	72 (63, 78)	86 (82, 90)
49-62 day (7+ week) interval between doses	346	12489	89 (87, 90)	91 (90, 92)	241	30329	85 (83, 87)	91 (90, 92)
84-111 days (12-15 weeks) since second dose								
21-34 day (3-4 week) interval between doses	8	167	80 (60, 90)	84 (68, 92)	11	833	75 (55, 86)	84 (72, 91)
35-48 day (5-6 week) interval between doses	13	285	81 (68, 89)	81 (67, 89)	19	1393	74 (60, 84)	86 (78, 91)
49-62 day (7+ week) interval between doses	240	6233	84 (82, 86)	89 (87, 90)	130	15689	84 (82, 87)	88 (85, 90)
112+ days (16+ weeks) since second dose								
21-34 day (3-4 week) interval between doses	30	396	69 (55, 79)	78 (68, 85)	12	1124	80 (65, 89)	85 (73, 92)
35-48 day (5-6 week) interval between doses	130	1705	69 (63, 74)	74 (69, 78)	11	847	76 (56, 87)	81 (66, 90)
49-62 day (7+ week) interval between doses	119	1596	70 (63, 75)	81 (77, 84)	26	6611	93 (89, 95)	91 (87, 94)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	
Two ChAdOx1 (AstraZeneca, Vaxzevria/COVISHIELD)								
14-27 days (2-3 weeks) since second dose								
21-34 day (3-4 week) interval between doses	0	10	NE	NE	17	103	NE	NE
35-48 day (5-6 week) interval between doses	1	16	NE	NE	4	2065	NE	NE
49-62 day (7+ week) interval between doses	7	522	95 (88, 97)	80 (57, 90)	26	2	96 (90, 99)	85 (60, 94)
28-55 days (4-7 weeks) since second dose								
21-34 day (3-4 week) interval between doses	2	8	NE	NE	139	15	NE	NE
35-48 day (5-6 week) interval between doses	7	59	51 (-6, 78)	51 (-8, 78)	3805	43	NE	NE
49-62 day (7+ week) interval between doses	68	1437	81 (75, 85)	75 (68, 81)	2	242	93 (88, 96)	84 (73, 90)
56-83 days (8-11 weeks) since second dose								
21-34 day (3-4 week) interval between doses	3	13	NE	NE	4119	37	NE	NE
35-48 day (5-6 week) interval between doses	9	92	60 (21, 80)	75 (51, 88)	9	215	52 (-29, 82)	58 (-14, 85)
49-62 day (7+ week) interval between doses	236	2721	65 (60, 69)	73 (69, 77)	103	4620	74 (66, 80)	75 (68, 81)
84-111 days (12-15 weeks) since second dose								
21-34 day (3-4 week) interval between doses	2	5	NE	NE	6	48	NE	NE
35-48 day (5-6 week) interval between doses	6	104	76 (46, 90)	83 (61, 92)	4	120	22 (-53, 60)	65 (31, 82)
49-62 day (7+ week) interval between doses	264	2839	62 (57, 67)	70 (65, 73)	25	1394	58 (49, 66)	72 (66, 77)
84+ days (12+ weeks) since second dose								
21-34 day (3-4 week) interval between doses	2	15	NE	NE	6	85	NE	NE
35-48 day (5-6 week) interval between doses	8	126	74 (47, 87)	81 (61, 91)	13	335	27 (-27, 57)	64 (37, 79)
49-62 day (7+ week) interval between doses	302	3058	60 (55, 64)	68 (64, 72)	128	6014	60 (52, 67)	72 (66, 77)
Unvaccinated	18809	76621	Reference		11366	212918	Reference	

VE=vaccine effectiveness; 95%CI=95% confidence interval; NE=Not estimable

¹ Unless otherwise specified, all VE estimates adjusted for age group (18-49, 50-69, 70-79, 80+ years); sex (male, female); individual epidemiological week (22-39); and region of the province.